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Abstract 
Tuberculosis (TB) is a major cause of global mortalities causing 1.6 million 
deaths in 2017 alone due to different species of Mycobacterium tuberculosis 
complex. Although Australia is a low TB burden country, a drop in current 
annual incidence by approximately 98% is required to achieve the World 
Health Organization’s TB elimination target by 2050. From a public health 
perspective, challenges exist with regard to tracing the source of TB and 
identifying factors underlying outbreaks of the disease. The availability of 
whole-genome sequencing (WGS) has enabled the exploration of the 
functional and evolutionary genomics of Mycobacterium tuberculosis, the 
detection of drug resistance conferring mutations, and the investigation of 
epidemiological clusters. 
In this thesis, genomic analysis was applied to a dominant outbreak strain 
of M. tuberculosis, the “Rangipo” strain from New Zealand. Whole-genome 
sequencing of nine isolates representing the Rangipo genotype was 
performed on an Illumina Miseq platform. The sequence data of each isolate 
was mapped to the reference M. tuberculosis strain H37Rv to generate a 
consensus genome. There were 700 single locus variants present across 
all of the outbreak isolates when compared to H37Rv. These included 
polymorphisms in 12 loci involved in the virulence of M. tuberculosis. For 
example, non-synonymous polymorphism was found in the two-component 
response regulator phoR gene that is essential for the growth of M. 
tuberculosis in macrophage and mice. Furthermore, de novo assembly was 
performed on the sequence reads that did not map to the reference genome 
iii 
 
H37Rv. This detected the presence of five additional virulence related 
genes in the outbreak strain that were absent in H37Rv. These included 
transcriptional regulator EmbR2, molybdopterin cofactor (MoCo) 
biosynthesis proteins A and B. MoCo is the cofactor for the narGHI encoded 
nitrate reductase which is involved in the adaptation of M. tuberculosis in 
hypoxic conditions and persistence in the guinea pig lungs. These results 
highlight the presence of additional virulence related genes in the Rangipo 
outbreak strain that are not present in the reference genome, H37Rv. 
Having successfully applied genomic analysis to a New Zealand outbreak 
strain, attention was then turned to TB in a local setting i.e. Tasmania, where 
published information on the molecular epidemiology of the disease was 
limited. I performed the whole-genome sequencing of M. tuberculosis 
isolated in Tasmania and analysed the genomic data together with public 
health surveillance records. A high proportion (>80%) of TB cases in 
Tasmania from 2014 to 2016 occurred in overseas born individuals. The 
whole-genome sequencing data determined the predominance of the East-
African Indian lineage 3 of M. tuberculosis followed by the Euro-American 
lineage 4, Indo-Oceanic lineage 1 and East-Asian lineage 2 among TB 
cases in Tasmania.  
Among the lineage 3 isolates, a possible cluster of TB was identified based 
on the single nucleotide polymorphism (SNP) difference being ≤5 for four of 
the isolates. Further investigation of the epidemiological data identified that 
the possible cluster of TB in Tasmania consisted of pulmonary TB cases 
reported in 2015 in patients originating from Nepal. In silico spoligotypes 
iv 
 
were generated for the clustered isolates and exactly matched the 
spoligotype of the dominant lineage 3 genotype, CAS1_Delhi in Nepal. This 
indicates that the probable origin of the strain of lineage 3 TB cluster cases 
in Tasmania was the Nepal region.  
One of the lineage 2 isolates was collected from a case of extrapulmonary 
TB which occurred in a 37-year-old male individual originally from Vietnam. 
The patient had earlier tested positive in interferon gamma release assay in 
2016 but did not exhibit the clinical signs and symptoms of pulmonary TB. 
Following an episode of colitis later in the year, the colon tissue biopsy 
specimen detected the presence of M. tuberculosis in the culture. The 
isolate was found to be resistant to isoniazid, rifampicin, pyrazinamide and 
ethambutol and therefore represented the first confirmed case of multi drug 
resistant (MDR) in Tasmania (TASMDR1). Epidemiological data revealed 
that a household contact of the Tasmanian MDR-TB patient was diagnosed 
with pulmonary MDR-TB in Vietnam in 2012. Both the 2016 Tasmanian and 
2012 Vietnamese isolates were acquired and upon genome sequencing 
were found to possess identical high confidence mutations to isoniazid, 
rifampicin, pyrazinamide, ethambutol and also streptomycin. In addition, the 
two isolates differed by less than 5 SNPs which is strongly indicative that 
the two patients were part of the same transmission network. It is highly 
likely that the Tasmanian case contracted the MDR-TB strain from his 
household contact in Vietnam and the infection remained in the latent stage 
before reactivating in the extrapulmonary form in Tasmania in 2016.  
v 
 
In conclusion, this study highlights that differences in the genome content 
of TB outbreak strains may be undetectable when M. tuberculosis sequence 
data is mapped with a single reference strain. Furthermore, I conclude that 
the epidemiology of TB in the low prevalence setting of Tasmania has 
features that resemble TB in other jurisdictions, for example, the presence 
of the clustered cases and drug resistance.   
vi 
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Chapter 1 
Tuberculosis: An Introduction 
 
1.1 Introduction 
Tuberculosis (TB) is an infectious disease caused by a group of bacteria 
categorised as the Mycobacterium tuberculosis complex (MTBC) that 
originated from a common African ancestral strain 35,000-15,000 years ago 
(Brosch et al., 2002; Gagneux, 2018). Based on genomic polymorphism 
data seven distinct phylogenetic lineages have been identified for the 
species M. tuberculosis (Firdessa et al., 2013; Gagneux et al., 2006). These 
different lineages of MTBCs differ with respect to their global distribution 
and in some cases the infectivity, transmissibility and drug resistance (Click 
et al., 2012; European Concerted Action on New Generation Genetic 
Markers and Techniques for the Epidemiology and Control of Tuberculosis, 
2006; Parwati et al., 2010; Reed et al., 2009). The human infection due to 
MTBC primarily affects the lungs (85% of all new and relapse cases 
worldwide) and is transmitted via airborne droplets (World Health 
Organization, 2017). However, a non-transmissible form affecting 
extrapulmonary body sites, for example, bone, joint, urogenital, ocular, 
gastrointestinal and other organs (Kulchavenya, 2014) accounted for 15% 
of global TB incidents in 2016 (World Health Organization, 2017). Patients 
with pulmonary TB (TB hereinafter) are classified as having active TB, latent 
TB and subclinical TB (Pai et al., 2016). The first group experience 
symptoms of TB (for example fever, weight loss and haemoptysis), transmit 
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infection and are usually detected by sputum smear microscopy and culture-
based diagnostic tests. Secondly, patients with latent TB, although infected, 
do not exhibit symptoms or transmit the infection and are undetectable in 
culture-based tests (Barry et al., 2009; Desikan, 2013; Esmail et.al, 2014). 
Thirdly, some patients with sub-clinical TB test positive for tubercle bacilli in 
their clinical samples and transmit the bacilli but do not demonstrate signs 
and symptoms associated with tuberculosis (Esmail et al., 2014). With 
approximately 1 billion deaths in the past 200 years (Ryan, 1994), TB has a 
significant impact on the public health and global economy. Tuberculosis 
causes a global loss of approximately 21 billion US dollars per year (Lewis 
et al., 2018)  primarily impacting the gross domestic productivity of high 
burden countries (Kirigia & Muthuri, 2016).  
 
1.2 Tuberculosis: Epidemiology  
TB transmits from person to person via air droplet nuclei particles that 
contain M. tuberculosis complex bacteria produced during coughing, 
sneezing or talking. They may also be produced during medical procedures, 
for example, induction of sputum and bronchoscopy (Diagnostic Standards 
and Classification of Tuberculosis in Adults and Children, 2000). 
Approximately 3,000 droplet nuclei are produced during a cough or a 5-
minute talk (Atkinson et al., 2009) which on average contains 1 -10 bacilli 
within its size of 1 -5 μM diameter (Lee, 2016). However, exposure does not 
always result in TB infection and disease. Tuberculosis is less infectious 
(average transmission of infection from source, 3 -10 people per year) (van 
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Leth et al., 2008) than measles that infects 90% of its non-immune contacts 
(Centers for Disease Control and Prevention, 2018). The factors that 
determine an effective transmission of TB include:- the load of bacilli 
generated from an infecting source, the concentration of organisms retained 
in the air after the expulsion, duration of exposure, and the immune status 
of the host (Diagnostic Standards and Classification of Tuberculosis in 
Adults and Children, 2000).  
Tuberculosis has now emerged as the most common cause of human 
mortalities due to a single infectious disease accounting for 1.6 million 
deaths in 2017 (World Health Organization, 2018d) as compared to 0.9 
million global deaths due to human immunodeficiency virus (HIV) in the 
same year (World Health Organization, 2018c). Approximately, 10 million 
people, including 9 million adults, globally contracted TB in 2017 (World 
Health Organization, 2018d). The recent global scenario showcases an 
uneven distribution of TB with countries on the lower side of the economy 
being affected the most. For example, India, Indonesia and Nigeria together 
consisted of 39% of total TB incidences worldwide in 2017. The World 
Health Organization (WHO) South-East Asia region dominated the total 
share of global TB incidence in 2017 (44%) followed by Africa (25%), the 
Western Pacific (18%) and minor proportions (13.2%) in Eastern 
Mediterranean, European and Americas collectively (Figure 1.1) (World 
Health Organization, 2018d). The annual incidence of TB cases (per 
100,000 population) varied from less than 10 in high income countries (for 
example, Australia) to between 150 -400 in the majority of heavily affected 
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countries (for example, India) and more than 500 in Mozambique, the 
Philippines and South Africa (World Health Organization, 2018d). 
 
Figure 1.1. Global distribution of Tuberculosis, 2017.  
Adapted with permission from the World Health Organization (2018). 
Copyright World Health Organization. 
  
In terms of treating new cases, a global success rate of 82% was achieved 
in 2016. In the past 17 years (2000 -2017), 42% deaths due to TB were 
avoided. However, the emergence of drug resistant TB has added to the 
challenge in TB control. Approximately, 1.6 million cases in 2017 were 
reportedly resistant to the first two anti-tuberculosis drugs, isoniazid and 
rifampicin or mono resistant to rifampicin. India, China and the Russian 
Federation accounted for almost half of these drug-resistant cases (World 
Health Organization, 2018d). Although TB has been a continuous threat to 
mankind, an improvement in terms of reducing global mortality (among HIV 
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negative patients) by 3% per year is being achieved. The mortality rate in 
the past 5 years declined fastest (11%) in the WHO European Region in 
2016, (World Health Organization, 2018d). The preventive Bacillus 
Calmette –Guérin (BCG) vaccines average coverage was more than 86% 
across all WHO regions (World Health Organization, 2017b). The WHO’s 
End TB Strategy and the United Nations’ Sustainable Development Goals 
focus to work “to end the global TB epidemic” for the period of 2016 -2035. 
This targets for the 80% decrease in TB incidence (new case per year) and 
90% reduction in TB related deaths by 2030 in comparison to figures in 2015 
(World Health Organization, 2016). To achieve the goal, increased funding 
in terms of the development of new diagnostics and achieving a 
technological breakthrough in TB control by 2025 has been advocated 
(World Health Organization, 2017).  
The transmission of TB from an active case is the major source of spread 
in endemic/epidemic settings and is evidenced by a large number (87%) of 
new TB cases in the top 30 high burden settings (Geng et al., 2002). In 
contrast, reactivation of latent TB accounts for most of the active cases 
(52%) in low TB burden countries and is common in foreign-born residents 
(Geng et al., 2002). Latent TB (LTB) is a hallmark of insufficient clearance 
of M. tuberculosis from the granulomatous lesion, thereby favouring 
bacterial persistence and their possible reactivation during an immune 
suppressed state of the host (Ulrichs & Kaufmann, 2006). A mathematical 
model estimated the global prevalence of LTB infection to be 1.7 billion 
people (approximate 1/3rd of the global population) in 2014 and is projected 
to add 16.5 cases per 100,000 per year in 2035 (Houben & Dodd, 2016). 
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Therefore, the TB control programs should cumulatively address the burden 
of active and latent TB to achieve WHO’s goal of eradicating the global 
burden of TB.  
1.2.1 Tuberculosis in Australia 
The collection of Australian TB notification data started in 1917 
(Communicable Diseases Intelligence, 2003). A steady decline in TB 
notifications was observed between 1918 to 1991 (90.2 versus 3.4 per 
100,000 population respectively), with an accelerated decrease starting in 
1952 when notification rates reached 55.4 per 100,000 population 
(Communicable Diseases Intelligence, 2003). Today, Australia is one of the 
low TB burden countries where 1442 cases (new and relapse) were notified 
among 24 million people in 2017 (World Health Organization, 2018). Eighty 
seven percent (n=1255) of TB cases in Australia were detected among 
those with known HIV status where 27 cases were associated with HIV 
positive individuals. Sixty two percent had pulmonary TB of which 87% were 
bacteriologically confirmed (World Health Organization, 2018). There were 
25 pulmonary TB cases identified as MDR/RR-TB during 2017 (World 
Health Organization, 2018). Although the national incidence rate is low in 
Australia, specific groups of people are at a high risk of developing the 
disease. For example, the incidence of TB in indigenous Australian is 6 
times higher than Australian-born non-indigenous people (Toms et al., 
2017). Similarly, overseas born population contribute a significant 
proportion of TB cases in Australia (86%, n=1151 out of 1339) and 
international students are more likely to develop TB while they are in 
Australia (Toms et al., 2017). The most common TB patient’s country of 
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origin (India, Vietnam, Philippines and China) in Australia (Toms et al., 
2017) are categorised under WHO’s high TB burden nations (World Health 
Organization, 2015b).   
1.3 Tuberculosis: Prevention through Vaccination 
For almost 80 years, BCG is the only globally accepted vaccine against 
tuberculosis. BCG was derived after attenuation of Mycobacterium bovis 
through 230 passages for 13 years (1908 -1921) (World Health 
Organization, 2013a). In terms of the evolution, BCG emerged as a result 
of the deletion of the RD-1 locus that encodes virulence related genes (open 
reading frames including RV3871 to Rv3879c), for example, 10-kDa 
cultured filtered protein (CFP-10) and 6-kDa early secreted-antigen 
(ESTAT-6) (Ganguly et al., 2008). The original BCG strain has undergone 
several passages and its descendants have been named differently, for 
example, BCG Tokyo, BCG Pasteur and BCG Russia. Genomic variation 
among BCG vaccine strains globally have been noticed (Abdallah et al., 
2015) but its effect on the efficacy in terms of protection was not evidenced 
in a systematic review including results from 18 clinical trials (Mangtani et 
al., 2014). The BCG vaccine confers protection against the progression to 
TB disease (Roy et al., 2014), extrapulmonary TB (Arbelaez, Nelson, & 
Munoz, 2000) and milliary TB (Trunz, Fine, & Dye, 2006). The protection 
was high in children who were strictly tested for their prior exposure to 
mycobacteria (rate ratio (RR), 0.26; 95% confidence interval (CI), 0.18-
0.37), or infants (RR, 0.41; 95% CI, 0.29-0.58) as compared to non-strictly 
tested children (RR, 0.59; 95% CI, 0.35-1.01) (Mangtani et al., 2014). The 
protection was weaker for the elderly irrespective of their test for previous 
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exposure to mycobacterial antigen (RR, 0.88; 95% CI, 0.59-1.31 and RR, 
0.81; 95% CI, 0.55-1.22, for tested and non-tested respectively) (Mangtani 
et al., 2014). For, extra pulmonary TB involving meninges and disseminated 
TB, protective efficacy was higher in tuberculin tested infants and children 
(RR, 0.1; 95% CI, 0.01-0.77 versus RR, 0.08; 95% CI, 0.03-0.25 
respectively) (Mangtani et al., 2014). The poor efficacy of BCG vaccine has 
been hypothesized to relate to previous exposure to Mycobacterium spp. 
(Black et al., 2002; Brandt et al., 2002). The BCG vaccine is given at birth 
and offers effective protection for the first 10 years of life (Rodrigues, 
Mangtani, & Abubakar, 2011). Vaccination is not recommended for 
protection against primary M. tuberculosis infection or revival of latent lung 
infection (World Health Organization, 2018a) and against leprosy and buruli 
ulcer (World Health Organization, 2017b). However, BCG is the only 
available vaccine for TB prevention. World Health Organization 
recommends an inoculation of a single dose of BCG vaccine at birth to all 
the infants born in high endemic areas except for those infected with HIV. 
In low incidence settings (for example, Western Europe, North America and 
Australia) vaccination should be scheduled to a high-risk group, including 
neonates immigrating from high risk countries or born to parents with a 
history of mycobacterial infection (World Health Organization, 2017b).  
 
1.4 Tuberculosis: Risk Factors  
The chances of progressing from infection to active TB is highest among 
infants aged less than a year (pulmonary disease, 30 -40%) (Marais et al., 
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2006). The risk lowers in children at their age of 2 -10 years (pulmonary 
disease, <5%) before rising high (pulmonary disease in 10-20%) after the 
age of 10 years (Marais et al., 2006). Childhood TB accounted for an 
approximate 6.9% of notified cases worldwide in 2016 (Swaminathan & 
Rekha, 2010). The gender wise distribution showed male predominance 
accounting 64% of total global TB incidences in 2017 (World Health 
Organization, 2018d). Infection with HIV is one of the most common risk 
factors for TB where 9% of people living with HIV were detected to have TB 
in 2017 and the majority (72%) of these cases were concentrated in Africa 
(World Health Organization, 2018d). In the same year, the death toll due to 
TB in the HIV-infected population reached 300,000 (23% of global TB 
mortalities) (World Health Organization, 2018d). Ford and colleagues in 
their systemic review involving 313,006 adults and 6,182 children with HIV 
reported TB as a major reason of hospitalization (18% and 10% 
respectively) and mortality (25% and 30% respectively) (Ford et al., 2015). 
Although the coexistence of HIV and TB have been widely reported 
(Friedland, Churchyard, & Nardell, 2007), only 0.5% of the worlds’ 
population live with HIV (World Health Organization, 2018c). Several other 
factors that increase the risk of acquiring TB in the general population have 
been identified (Table 1) (Dheda, Barry, & Maartens, 2016). These include 
health, socio-behavioural and environmental aspects, for example, 
diabetes, overcrowding, alcohol consumption and exposure to biomass fuel 
smoke respectively. It is therefore essential to consider all these factors to 
define the paradigm of tuberculosis.  
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Table 1. Risk factors of developing tuberculosis and activation of latent infection.  
Risk Factors Risk of developing  active TB (folds) 
Risk of conversion of latent  
TB (presumed) to active TB (folds) 
HIV 20-40 50-100 
Silicosis 3-4 30 
Chronic renal failure requiring dialyses 7-50 10-25 
Recipient of glucocorticoid treatment 2 4.9 
Diabetes 3 2-3.6 
Malnourished or underweight 12 2-3 
Biomass fuel exposure 2 Insufficient data 
Alcohol misuse 3 1.5 
Male sex (after adolescence) 2 Insufficient or discordant data 
Age High, <4 and >20 years 2.2-5.0 (when infected before ≤4 years 
Malignancy 4-5 1 6 (head and neck carcinoma) 
Immunosuppression related to transplant 15-20 20-74 
COPD 2 (inhaling corticosteroid) Insufficient data 
Overcrowding and poverty Increased risk Increased risk 
Recent TB infection (≤ 2 years) NA 15.0 
Apical fibronodular change in chest radiograph NA 6-19 
 
Reproduced with permission from Dheda et al. Lancet (2016). Copyright Elsevier Ltd. 
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1.5 Tuberculosis: Clinical Presentations 
Tuberculosis was previously named as phthisis, king’s evil, consumption, 
lupus, white plague and captain of all these men of death (Barberis et al., 
2017). The clinical manifestation of pulmonary TB onsets gradually, 
approximately weeks to months after infection (Diagnostic Standards and 
Classification of Tuberculosis in Adults and Children, 2000). The active form 
of TB develops in about 5-10% of exposed individuals. Initially, paratracheal 
lymphadenopathy may develop due to the spread of bacilli through 
lymphatic channels. The bacteria may reach the pleura of lungs and cause 
effusion and exhibit symptoms including fever, pleuritic pain and dyspnoea 
(shortness and difficulty in breathing). The physician may notice poor breath 
sounds and dullness to percussion as a sign of pleural effusion (Diagnostic 
Standards and Classification of Tuberculosis in Adults and Children, 2000; 
Knechel, 2009). The most evident symptom is a non-remitting persistent 
cough that is reported in 95% cases (Davies, Gordon, & Davies, 2014). 
However, patients also experience fever (75%), night sweats (45%) and 
loss in body weight (55%) (Davies, Gordon, & Davies, 2014), progressive 
fatigue and malaise (Knechel, 2009). In addition, streaks of blood in sputum 
may be noticed as a result of ruptured cavitary blood vessels in the lungs 
(Knechel, 2009).   
Individuals with latent TB are non-symptomatic and do not transmit the 
disease (Pai et al., 2016). The latency in TB may convert to active form if 
viable bacilli in the necrotic tissues reactivate following a loss in the host's 
immunity, for example, HIV infection, age (≥65 years), progressive diabetes 
mellitus, kidney failure, poor nutrition, smoking, drug therapy and organ 
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transplantation (Frieden et al., 2003; Thrupp et al., 2004). People coinfected 
with HIV and TB may either present with classic symptoms of TB or are 
poorly symptomatic ( Lee et.al., 2000). As the disease progresses from HIV 
infection to acquired immune deficiency syndrome (AIDS), the chances of 
developing cavitary lesions are less likely and TB is poorly diagnosed 
clinically, both by chest radiography and sputum smear examination (Kwan 
& Ernst, 2011). Therefore, the TB infectious period of HIV positive 
individuals is lower than those without HIV (2 months versus 11 months 
respectively) (Corbett et al., 2004). Extrapulmonary TB (EPTB) in at least 
one site is detected in 60% patients with AIDS as compared to those without 
AIDS (p<0.001) (Chaisson et al., 1987). The risk of developing EPTB 
increases with waning immunity as indicated by a drop in CD4 T lymphocyte 
cell counts, for example, 70% in patients with CD4 cell/µL ≤100 and 28% in 
those with CD4 cells/ µL count of more than 300 (Jones et al., 1993). This 
decline in CD4 T lymphocyte count is also associated with the dissemination 
of TB through the blood circulation. Mycobacterium tuberculosis was 
detected in blood specimen of 49% patients with CD4 cell/µL ≤100 while 
none in those with the count of more than 300 CD4 cells/ µL (Jones et al., 
1993). 
In children, poor bacteriological and radiographic evidence complicates the 
diagnosis of TB (Eamranond & Jaramillo, 2001). Marias and colleagues in 
their critical review including prechemotherapy literature classified children 
into high risk group (age <3 years and/or immune compromised) and low 
risk (age >3 years and/or immune competent). In the former, patients 
presented with non-remitting and persistent symptoms and occasionally 
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had an acute onset and frequently progressed to the disease. In the low risk 
group, conversion from infection to disease was rare but patients clinically 
presented with symptoms related to the high-risk group (non-remitting and 
persistent symptoms) (Marais et al., 2006).  
 
1.6 Tuberculosis: Diagnosis 
 
1.6.1 Chest Radiography  
The radiological imaging of chest using X-ray (CXR) has long been used to 
diagnose pulmonary TB (World Health Organization, 2012). The diagnosis 
of bacteriologically unconfirmed TB is collectively done by assessing the 
clinical features and CXR report (World Health Organization, 2014a). 
Tewolde et al. reported the common CXR observations of 159 smear 
negative pulmonary TB cases where consolidation was detected in a 
majority of CXR films (40.3%) followed by cavitation (23.9%) and nodular 
lesions (17.0%) (Tewolde et al., 2015). The lung radiological observation is 
independent of the duration of infection and shows upper lobe cavitation in 
adults and immunocompetent host whereas lower lung inflammation, 
adenopathy and effusion in patients with compromised immune status 
(Rozenshtein et al., 2015). The utility of CXR in TB screening has been 
reported from a prevalence study where 5% of 1.2 million immigrants and 
refugees displayed evidence of TB (World Health Organization, 2012). This 
shows the applicability of CXR in finding a significant number of TB cases 
in a pool of healthy population (World Health Organization, 2012). World 
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Health Organization’s guideline to manage latent TB in resourceful 
countries with less than 100 cases per 100,000 population recommends 
examining symptoms of TB and perform CXR prior to the initiation of drug 
therapy (World Health Organization, 2015a). However, in a hospital setting 
of Nepal, Kumar and colleagues involved 25 physicians to assess 75 CXR 
films and found a poor specificity (51%) but higher sensitivity (71%) of CXR 
in diagnosing pulmonary TB (Kumar et al., 2005). The authors highlighted 
the possibility of over-diagnosis and treatment owing to the poor specificity 
of CXR in a resource limited setting (Kumar et al., 2005). A recent advent in 
computed tomography is being considered to be a more sensitive imaging 
technique to detect TB, lymphadenopathy, bronchogenic spread, 
differentiating active versus inactive disease and LTB infection more 
specifically in a patient with higher risk of activation and on drug therapy 
(Alkabab et al., 2018; Lyu et al., 2011; Piccazzo et al, 2014; Skoura, Zumla, 
& Bomanji, 2015). 
 
1.6.2 Laboratory Diagnosis  
 
1.6.2.1 Testing for Latent TB Infection 
World Health Organization recommends the use of tuberculin skin test 
(TST) or interferon-gamma release assay (IGRA) depending upon their 
availability and affordability for the detection of latent TB (World Health 
Organization, 2015a). These tests are not targeted to diagnose the case or 
suspected case of active TB. For HIV-TB coinfection, these tests are highly 
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recommended to detect cases of LTB infection. However, their unavailability 
should not limit the initiation of therapy in HIV positive individuals or children 
aged < 5 years with household TB contact (Organization, 2018c). Patients 
detected positive in either TST or IGRA should undergo CXR before 
selecting treatment for latent TB, TB or any other lung diseases (World 
Health Organization, 2015a).  
 
1.6.2.2 Systematic Screening of Active TB  
World Health Organization advocates the systematic screening for the early 
detection of TB and initiation of treatment (World Health Organization, 
2013). This includes rapid detection of expected TB cases in specific 
groups. For example, contacts of active cases, people living with HIV and 
workers with a history (current or previous) of silica exposure. The guideline 
also attracts prison inmates, people with fibrosis in the chest (as detected 
in CXR), residents in high-risk settings or seeking health service living in an 
area where TB prevalence is ≥100 per 100,000 population, vulnerable 
people with poor access to health care or in places where the TB prevalence 
rate is ≥ 1% (World Health Organization, 2013). 
The systematic screening involves an initial assessment based on an 
interview regarding TB symptoms and HIV status. This is then followed by 
CXR in suspected cases. For adults without HIV, sputum smear 
examination is followed by a highly accurate molecular test (for example, 
Xpert MTB/RIF) for both the smear-positive and smear-negative TB cases. 
Interpretation of these tests results may require re-testing, growing the 
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bacilli in a culture medium, drug-susceptibility testing and clinical correlation 
(World Health Organization, 2013). Systematic screening of TB does not 
include the gold standard culture-based tests due to their longer turnaround 
time and resource allocation. However, for discrepant screening results and 
upon the availability of adequate facilities, culture-based identification and 
drug susceptibility testing is recommended (World Health Organization, 
2013).  
 
1.6.2.3 Whole-Genome Sequencing in Diagnosis and Predicting Drug 
Susceptibility of M. tuberculosis 
Whole-genome sequencing (WGS) allows the investigation of the entire 
genomic region of a microorganism (Schwarze et al., 2018). The high 
throughput next-generation sequencing (NGS) method is based on 
sequencing by synthesis technology (Buermans & den Dunnen, 2014) and 
has been applied to generate whole-genome sequence data for the routine 
characterization (Votintseva et al., 2017), drug susceptibility testing (Witney 
et al., 2015), genotyping (Amlerova, Bitar, & Hrabak, 2018; Guthrie et al., 
2018) and epidemiological investigations of tuberculosis (Gautam et al., 
2018). Whole-genome sequencing poses an advantage to ideally identify all 
the clinically relevant mutations and predict a wide range of drug resistance 
determining mutations (Wells et al., 2013) as compared to Xpert MTB/RIF 
and line probe assays which are limited to detect mutations in specific gene 
locus (Sanchez-Padilla et al., 2015). Furthermore, WGS can identify 
mutations that confer resistance to new drugs, for example, bedaquiline and 
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delamanid (Bloemberg, Gagneux, & Böttger, 2015). In terms of clinical 
application, a multi-centre study involving eight laboratories across Europe 
and North America reported an accuracy of 93% for species identification 
and drug susceptibility testing using WGS (Pankhurst et al., 2016). The 
study linked 15 out of 91 cases to an outbreak and identified a new cluster 
of TB due to multi-drug resistant strains of M. tuberculosis. Furthermore, 
WGS generated reports 21 days earlier than the existing algorithm, resulting 
in an annual financial saving of 7% (Pankhurst et al., 2016). Votintseva and 
colleagues recently reported the utility of WGS in detecting and drug 
susceptibility testing of M. tuberculosis directly from clinical specimen 
(Votintseva et al., 2017). Mycobacterium tuberculosis was identified in all 
the DNA extracts from 39 out of 40 smear positive respiratory samples (95% 
to species level) (Votintseva et al., 2017). The genotypic drug susceptibility 
result was available for 62% (n=24) cases and were all comparable to 
phenotypic observation. In terms of cost and turnaround time, Illumina 
MiSeq platform was cheaper than Illumina MiniSeq (£96 versus £198 per 
sample) but required an additional 28 hours to generate (44 versus 16 
hours) the results (Votintseva et al., 2017). Similarly, Brown et al. introduced 
biotinylated RNA baits to specifically capture M. tuberculosis DNA during its 
extraction from sputum and performed WGS where sequence data of high 
quality (read depth >20 times and coverage >90%) was obtained from 20 
out of 24 smear positive specimens and one smear positive but culture 
negative case (Brown et al., 2015). The WGS based genotypic drug 
susceptibility testing was similar to those observed using phenotypic 
methods (Brown et al., 2015). However, one report suggests potential 
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contamination due to human genome that leads to the poor prediction of 
drug resistance when clinical specimen is directly sequenced for M. 
tuberculosis (Doughty et al., 2014). The availability of user-friendly open 
source tools and databases (for example, PhyResSE (Feuerriegel et al., 
2015), TBProfiler (Coll et al., 2015), TGS-TB (Sekizuka et al., 2015) and 
Mykrobe Predictor (Bradley et al., 2015) to analyses the genomic data of M. 
tuberculosis aids in translating WGS from research to the diagnostic 
laboratories. However potential limitations in its application to routine 
diagnostics include cost, technical requirement and standardization of 
bioinformatic pipelines (Lee & Pai, 2017). 
World Health Organization is soon likely to publish a technical guideline 
addressing the application and interpretation of DNA sequencing 
technology in TB diagnostics. In addition, availability of a robust description 
of high confidence mutations of clinical utility that are related to drug 
resistance in M. tuberculosis will likely lead to the extension of WGS to 
clinical settings (World Health Organization, 2018d).  
 
1.7 Tuberculosis: Pathogenesis 
 
1.7.1 Taxonomic Hierarchy and Microbiology of M. tuberculosis 
Kingdom    Bacteria 
Phylum    Actinobacteria 
Suborder    Corynebacterineae 
Family    Mycobacteriaceae 
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Genus    Mycobacterium 
Species    Mycobacterium tuberculosis 
The genus, Mycobacterium encompasses 170 members reported until 2017 
(Forbes, 2017). The genome, seven members of M. tuberculosis complex 
including M. tuberculosis, M. canettii, M. africanum, M. bovis, M. microti, M. 
pinnipedii, and M. caprae share 99.9% sequence similarity at 16S rRNA 
nucleotide level (Brosch et al., 2002; Ernst, Trevejo-Nuñez, & Banaiee, 
2007). Based on the DNA-DNA hybridization and average nucleotide 
identity similarity, Riojas and colleagues have formally proposed 
reclassification of M. tuberculosis, M. africanum, M.bovis, M.caprae, M. 
microti and M. pinnipedi as the heterotypic synonym of M. tuberculosis 
(Riojas et al., 2017). Mycobacterium tuberculosis is not identified in Grams’ 
stain preparation due to the abundant lipid content in their cell envelope 
(40% cellular dry mass) (Koch & Mizrahi, 2018). The cell wall of M. 
tuberculosis contains a thick layer of peptidoglycan, lipids, glycolipids and 
polysaccharide, for example, mycolic and mycocerosic acid, 
phenolthiocerol, lipoarabinomannan and arabinogalactan (Cole et al., 
1998). Furthermore, the tubercle bacilli are acid-fast (i.e. cell wall resists 
acid decolorization), do not possess flagella for motility, non-spore-forming, 
require oxygen for survival (i.e. obligate aerobe) and often form beads in the 
culture media (Dunn, Starke, & Revell, 2016). The bacterium resembles 
Mycobacterium leprae in terms of its intracellular habitat, but unlike leprosy 
bacillus, M. tuberculosis can be retrieved in bacterial culture media (Bhat & 
Prakash, 2012; Liu et al., 1973). Although M. tuberculosis can synthesize 
all the amino acids and cofactors for enzymatic reactions, it is a slow grower 
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and requires approximately 22 hours to double its number in a growth 
medium (Koch & Mizrahi, 2018; Roetzer et al., 2013) as compared to 20 
minutes for Escherichia coli (Sezonov, Joseleau-Petit, & D'Ari, 2007). This 
has been related to the slower polymerization rate (20 times less as 
compared to Escherichia coli) of a protein FtsZ in M. tuberculosis that is 
responsible for cell division and cell wall biosynthesis (Hett & Rubin, 2008). 
1.7.2 Evolution and Molecular Clock of M. tuberculosis  
The modern M. tuberculosis complex strains have lost several repeat 
regions during the evolutionary process (Arnold et al., 2006). These 
deletions may be a non-functional phenotypic marker or potentially related 
to the survival and expansion of the bacillus (Arnold et al., 2006). 
Mycobacterium africanum type 1, the ancestor of M. microti and M. bovis 
lost spacer 39 and differed from M. tuberculosis that did not possess spacer 
34. This M. tuberculosis that is absent for specific deletion region (TbD1) 
emerged as modern strains (for example H37Rv, Beijing) and those that 
were deleted for spacers 29-32 and 34 diverged as ancient strains (for 
example atypical Mycobacterium) (Arnold et al., 2006). Although the 
members of M. tuberculosis complex are closely related in terms of their 
16S rRNA composition (99.9% similarity at the nucleotide level), they 
significantly differ in ecotypes and infectivity (Brosch et al., 2002). For 
example, M. tuberculosis, M. africanum and M. canettii are exclusively 
human pathogens whereas M. microti’s habitat is in rodents and M. bovis 
has a wide range of host tropism (Brosch et al., 2002). 
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The concept of the M. tuberculosis complex molecular clock is based on 
estimating the number of mutations across the whole-genome per unit time 
(Barbier & Wirth, 2016). This has been important in studying the evolution 
of M. tuberculosis and genomic variations in M. tuberculosis acquired over 
a period of time (Arnold, 2007). Different studies have reported the 
occurrence of 0.3-0.5 single nucleotide polymorphism per year/genome of 
M. tuberculosis (Bryant et al., 2013; Roetzer et al., 2013; Walker et., 2013). 
This corresponds to 1*10-7 substitutions per nucleotide per year (Barbier & 
Wirth, 2016) which is lower than Staphylococcus aureus (Nübel et al., 
2010), Escherichia coli (Wielgoss et al., 2011) and mis -match repair lacking 
Helicobacter pylori (Didelot et al., 2013) (2*10-6, 5*10-6 and 1*10-5 
respectively). Based on the changes in the IS6110 element, it is estimated 
that two strains of M. tuberculosis separate apart in 3.2-8.7 years (de Boer 
et al., 1999; Warren et al., 2002; Warren et al., 2002). However, this rate of 
genetic change differs between the lineage types of M. tuberculosis (Kato-
Maeda, Metcalfe, & Flores, 2011). The estimation of mutation rate may be 
affected by the intra-chromosomal variations, lineage difference and stages 
of infection (for example active versus latent). This calculation may be 
further complicated by the presence of highly variable repetitive regions 
prone to mutation (for example, PE-PGRS, PPE and ESX families) and their 
possible omission during the genomic data analyses (Barbier & Wirth, 
2016). The molecular clock estimate of M. tuberculosis is being increasingly 
applied in molecular studies of TB, particularly to establish the 
epidemiological links between the cases, trace the source and their contacts 
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to define the events of TB transmission (Bryant et al., 2013; Roetzer et al., 
2013; Walker, et al., 2013).  
 
1.7.3 Lineage Classification of M. tuberculosis  
The availability of whole-genome sequencing has revealed considerable 
genomic variations among/within the species of M. tuberculosis 
(Fleischmann et al., 2002; Gautam et al., 2017; Ioerger et al., 2010; Zheng 
et al., 2008). This resulted in large sequence polymorphism (LSPs) and 
single nucleotide polymorphism (SNPs) as an unambiguous and robust 
method for phylogenetic classification of M. tuberculosis (Filliol et al., 2006; 
Kato-Maeda et al., 2001). The less likelihood of occurrence of SNP, 
horizontal gene transfer and re-acquisition of deleted regions in M. 
tuberculosis complex makes SNP and LSP based evolutionary 
classification more ideal and informative (Filliol et al., 2006; Gagneux et al., 
2006; Gutacker et al., 2002; Mostowy et al., 2002).  
Mycobacterium tuberculosis has been categorised into different genetic 
lineages. Gagneux and colleagues’ classification into six lineages (L1 - L6 
respectively) was based on the presence of large sequence polymorphisms, 
for example RD239 (L1, Indo-oceanic), RD105 (L2, East Asian), RD750 (L3, 
East African-Indian), Pks15/1 7bp (L4, Euro-American), RD711 (L5, West 
African I), RD702 (L6, West African II) (Gagneux et al., 2006). Recently, 
Lineage 7 M. tuberculosis “Aethiops vetus” (Nebenzahl-Guimaraes et al., 
2016) has been reported among the strains isolated in Ethiopia (Comas et 
al., 2013; Firdessa et al., 2013). These Ethiopian strains were 
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phylogenetically closer to L1 East African-Indian (EAI), possessed TbD1 
region, RvD1-RvD5 and RD239 (or LSP 239) and had deletions in mmp19, 
IppH, IppO/sseB, Rv3467/rmlB2/mhpE (Nebenzahl-Guimaraes et al., 
2016). Different lineages of MTBCs are either geographically restricted (for 
example L5, L6 and L7) or are widespread (for example L2 and L4) (Figure 
1.2) (Gagneux, 2018). I will follow the Gagneux lineage classification 
hereinafter.
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Figure 1.2. Genomic changes during the evolution of MTBC and global distribution of its different lineage types. 
 The colour codes in the map and phylogenetic tree represent each lineage of M. tuberculosis as indicated in the later. The 
triangles represent collapsed branches (for clarity) of the main M. tuberculosis complex lineages.  
Adapted with permission from Gagneux, Nat Rev Microbiol. (2018). Copyright Springer Nature Limited. 
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Various studies have reported the dominant presence of lineage of M. 
tuberculosis circulating in their country of origin among overseas born 
individuals. Yen and colleagues in their New Zealand based study 
predominantly detected lineage 2 among patients born in East Asia (34/46, 
73.9%) (Yen et al., 2013). Gagneux and colleagues hypothesized that 
“lineages that are rare in a specific human population are not adapted to 
transmit and cause secondary cases in this specific human population” 
(Gagneux et al., 2006). Furthermore, the authors reported that patients born 
in the US to Chinese and Filipino parents were detected with strains 
common in China and Philippines, i.e. East-Asian and Indo-oceanic 
respectively (p <0.001) respectively (Gagneux et al., 2006). This sympatric 
combination between a specific lineage of M. tuberculosis complex and 
geographic origin of the patient has been associated with clinic-
epidemiology of tuberculosis (Gagneux et al., 2006) and may be related to 
the presence of latent TB acquired in the home country prior to their arrival 
in the new setting. However, some lineages, for example, lineage 4 is 
globally distributed but is restrictive in terms of geographic presence of its 
sub-lineages (Stucki et al., 2016).  
 
1.8 Tuberculosis: Chemotherapy and Drug Resistance  
 
1.8.4.1 Therapeutic Approach 
Tuberculosis is a preventable and curable disease (Reichman, 1997). 
Ironically, after 25 years of its declaration of global emergency, TB is now a 
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leading cause of deaths (World Health Organization, 2018d). The aim of TB 
therapy is to completely treat the disease ensuring no reversions, prevent 
mortalities, disrupt the transmission and prevent the development of drug 
resistance (du Toit, Pillay, & Danckwerts, 2006). It was during 1944 -1976 
the major anti-TB drugs (for example, isoniazid, streptomycin, rifampicin) of 
current TB treatment regime were introduced (Chaisson, 2003). These 
antibiotics not only treat the disease but also rapidly decrease the 
infectiousness of the sources thereby limiting the spread of M. tuberculosis 
(Schwartzman & Menzies, 2000). Isoniazid is lethal in the initial stage of 
infection killing almost 95% bacilli within the first two days whereas 
rifampicin is active against persisting mycobacteria in the later stage of 
infection (Joshi, 2011). The current WHO guideline for the treatment of drug 
susceptible TB includes 6 months of rifampicin-based therapy which 
contains an intensive phase of 2 months (Isoniazid (H), Rifampicin (R), 
Pyrazinamide (Z) and Ethambutol (E)) followed by 4 months of continuation 
of H and R (World Health Organization, 2017a). Treatment of TB, therefore, 
involves one of the longest regimes directed against infectious disease 
(Namasivayam et al., 2017). In terms of HIV infection, antiretrovirals should 
be administered to all TB patients irrespective of their CD4 T lymphocyte 
cell count and TB treatment should be done for 6 months. Management of 
tubercular meningitis should include addition of corticosteroid over the 
period of 6-8 weeks. Children should be treated with the same regime as for 
an adult, i.e. 2 months HRZE followed by 4 months HR (World Health 
Organization, 2014b). In addition to the chemotherapy, provisions for patient 
care and the directly observed treatment administered by trained personnel 
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at home or community should be ensured (World Health Organization, 
2017a).  
To treat latent TB in both the adults and children in high and low burden 
settings, six months monotherapy with isoniazid is recommended. In high 
burden areas an alternative three months daily isoniazid and rifampicin (for 
individuals aged <15 years) or three months weekly isoniazid and 
rifapentine for adults and children should be offered. In low incidence 
settings, treatment regime including nine months isoniazid or three to four 
months isoniazid and rifampicin or three months weekly isoniazid and 
rifapentine or three to four months of rifampicin monotherapy is 
recommended. People living with HIV should receive an isoniazid 
preventive treatment (36 months for adults and adolescents and for 6 
months to children ≥12 months, infants <12 months and children with 
successful TB treatment) (World Health Organization, 2018e). The Centers 
for Disease Control and Prevention recommends 9 months of isoniazid 
chemoprophylaxis for immigrants with latent TB (Centers for Disease 
Control and Prevention, 2012).  
In terms of drug development, as of 2018, 20 new anti-TB drug candidates 
are in different phases of development (World Health Organization, 2018d). 
This includes two drugs (bedaquiline and delamanid) that have been 
accelerated with regulatory conditions for TB treatment (World Health 
Organization, 2013b; World Health Organization, 2014c). In addition, seven 
drugs have been repurposed for their inclusion in treatment and include 
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clofazimine, linezolid, levofloxacin, moxifloxacin, nitazoxanide, rifampicin 
(high dose) and rifapentine (World Health Organization, 2018d). 
1.8.4.2 Tuberculosis: Drug Resistance  
Drug resistant TB is emerging as a global threat with a record number of 
160,684 multi-drug resistant/rifampicin resistant (MDR/RR) cases in 2017 
(an approximate 5% increase since 2016) (World Health Organization, 
2017; World Health Organization, 2018d). The incidence of MDR/RR-TB 
was highest in previously treated cases (18%) than in new cases (3.5%) in 
2017. India (24%), China (13%) and Russian Federation (10%) collectively 
accounted for 47% of global MDR/RR-TB cases (World Health 
Organization, 2018d). In terms of therapy, low success rate was recorded 
(55% globally) and a big gap was realized in terms of enrolment for 
treatment with second-line drugs (enrolment proportion, 25% in 2017 versus 
87% in 2016) mainly in India and China (40% of the total gap) (World Health 
Organization, 2018d). 
Mycobacterium tuberculosis resistant to at least the two first line anti-TB 
drugs, isoniazid and rifampicin is defined as multi-drug resistant isolate. 
These isolates, if they retain resistance to at least one of the second line 
injectable drugs (kanamycin, amikacin or capreomycin) and a 
fluoroquinolone, are regarded as extensively-drug resistant M. tuberculosis 
(World Health Organization, 2018d). The drug resistance TB may be 
acquired when the susceptible isolate develops to a resistant form within 
the host or due to the spread of the drug resistant strain itself (Joshi, 2011). 
Drug resistance in M. tuberculosis results from chromosomal mutations 
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(Gygli et al., 2017) and develops as a result of the accumulation of drug 
resistant progeny (Veen, 1995) rather than the horizontal transfer of 
resistance determining genes (Cole et al., 1998), plasmids or mobile 
elements (Gygli et al., 2017). The development of drug resistance in M. 
tuberculosis has been described as a “man-made problem” (Kochi, 
Vareldzis, & Styblo, 1993) arising due to poor chemotherapy and a result of 
“careless care” (Raviglione, 2006). Drug resistance in TB can develop 
during treatment for active TB due to “inadequate clinical care or drug 
management”, for example, incomplete treatment, prescription of the wrong 
regime in terms of type and dose or unavailability and/or poor quality of 
drugs (World Health Organization, 2018g). Liang and colleagues identified 
a higher number of re-treated patients acquiring MDR-TB (5.48 fold higher 
than new cases) and improper drug therapy as a factor for the development 
of MDR-TB (Liang et al., 2012). Similarly, age, living in a single roomed 
house, previous treatment and a history of HIV infection has been identified 
as independent predictors for MDR-TB (Workicho, Kassahun, & 
Alemseged, 2017). In addition, patients felt that poor economy, adverse 
effect of drugs and lack of knowledge as being factors associated with MDR-
TB development (Liang et al., 2012).  
Mycobacterium tuberculosis is intrinsically resistant to some of the 
commonly used anti-bacterial drugs, for example, beta lactams (Abraham 
et al., 1941). However, the acquisition of chromosomal mutations that 
results in M. tuberculosis drug resistance are clinically correlated. These 
mutations may include single or multiple events that confer resistance of M. 
tuberculosis to anti- tuberculosis drugs (Table 2) (Gygli et al., 2017). 
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Table 2. Drug resistance determining mutations in M. tuberculosis. 
Antibiotics Gene target Mechanism of resistance Reference 
Rifampicin rpoB Drug target alteration (Telenti et al., 1993) 
Isoniazid katG Abrogated drug target (Heym et al., 1995) 
inhA Drug target alteration (Banerjee et al., 1994) 
inhA promoter Drug target overexpression (Morlock et al., 2003) 
Ethambutol embB Drug target alteration (Sreevatsan et al., 1997) 
Pyrazinamide 
pncA Abrogated prodrug activation 
(Konno, Feldmann, & McDermott, 
1967) 
Ethionamide inhA Drug target alteration (Banerjee et al., 1994) 
 inhA promoter Drug target overexpression (Morlock et al., 2003) 
 ethA Abrogated prodrug activation (Morlock et al., 2003) 
Fluoroquinolones gyrA/B Drug target alteration (Takiff et al., 1994) 
Streptomycin Rrs Drug target alteration (Meier et al., 1994) 
rpsL Drug target alteration (Meier et al., 1994) 
Amikacin Rrs Drug target alteration (Alangaden et al., 1998) 
Kanamycin Rrs Drug target alteration (Alangaden et al., 1998) 
 eis promoter Overexpression of drug inactivating enzyme (Kambli et al., 2016) 
Capreomycin Rrs Drug target alteration (Maus, Plikaytis, & Shinnick, 2005) 
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tlyA Abrogation of drug target methylation (Maus, Plikaytis, & Shinnick, 2005a) 
P-aminosalicylic acid thyA Drug target bypassing (Zhao et al., 2014) 
 Folc Abrogation of prodrug activation (Zhao et al., 2014) 
Cycloserine Ald Overabundance of drug target substrate (Desjardins et al., 2016) 
Alr Drug target alteration (Desjardins et al., 2016) 
alr promoter Drug target overexpression (Desjardins et al., 2016) 
Bedaquiline atpE Drug target alteration (Huitric et al., 2010) 
Promoter/mmpR Overexpression of efflux pump Mmpl5 (Hartkoorn, Uplekar, & Cole, 2014) 
Linezolid rplC Drug target alteration (Beckert et al.) 
Rrl Drug target alteration 
(Hillemann, Rüsch-Gerdes, & 
Richter, 2008) 
Delamanid/Pretomanid Ddn Abrogation of prodrug activation (Haver et al., 2015) 
Clofazimine Promoter/mmpR Overexpression of efflux pump Mmpl5 (Hartkoorn et al., 2014) 
 
Reproduced with permission from Gygli et al. FEMS Microbiol Rev. (2017). Copyright Federation of European Microbiological 
Societies. 
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The World Health Organization has issued general principles to guide the 
treatment of MDR-TB (World Health Organization, 2014). This recommends 
the treatment of MDR-TB with at least four second line drugs including an 
injectable (for example, amikacin, capreomycin, and kanamycin) and 
pyrazinamide even if evidence of effectiveness is not clear with any of these 
drugs. In case the recommended drugs meet a criterion of “likely to be 
effective”, treatment should include ethionamide or prothionamide. The 
treatment course may extend up to 20 months for new MDR-TB cases and 
is modifiable with respect to culture conversion and patients’ reaction to the 
drugs (World Health Organization, 2014). This longer duration of therapy 
may add up the additional challenge in TB control, for example, poor 
compliance and treatment failure leading to continued TB transmission 
(Namasivayam et al., 2017). The World Health Organization has introduced 
a shorter MDR-TB regimen including, 4-6 months of kanamycin-
moxifloxacin-prothionamide-clofazimine-pyrazinamide-isoniazidhigh-dose -
ethambutol followed by 5 months of moxifloxacin-clofazimine -
pyrazinamide-ethambutol (World Health Organization, 2015). However, this 
is not recommended for those displaying resistance to shorter regime drugs 
(excluding isoniazid) or have been exposed to TB for ≥1 month or developed 
intolerance to these drugs or for the treatment of extra-pulmonary TB and 
during pregnancy (World Health Organization, 2015). In terms of HIV 
coinfection, antiretrovirals should be added to the MDR-TB drug regime 
irrespective of immune status based on the CD4 T lymphocyte cell count 
(World Health Organization, 2014). After 40 years, WHO issued an interim 
guideline for inclusion of the new anti-TB drug, bedaquiline in combination 
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therapy for MDR-TB (World Health Organization, 2013b). Bedaquiline 
together with delamanid was “justified” to treat TB in those patients left with 
fewer options of the drug of choice (Andrey et al., 2017). 
 
1.9 Epidemiological Typing of M. tuberculosis 
Typing of bacterial populations enables one to study their relationship within 
the members of the same species or wider category. This can further be 
applied in epidemiological studies, for example, tracing the source of 
infections/outbreaks, identify transmission chains either in the community or 
hospital settings, determine pathogenic strains, designing surveillance 
strategies and evaluating control measures (MacCannell, 2013; Struelens, 
1998). Conventionally, bacterial species have been typed based on their 
phenotypic properties, reactions towards antigen, antibody or biochemicals, 
and susceptibilities towards phage and antibiotics (Foxman et al., 2005).  
The epidemiological typing of M. tuberculosis is an important tool for the 
tuberculosis control strategy (Cannas et al., 2016) particularly due to the 
global distribution tuberculosis, airborne nature of its spread, clonality in 
origin, lineages and sub-lineages categories of infecting pathogen, 
prolonged latency of infection, varying efficacy of BCG vaccination, 
inapparent clinical signs and potential to cause outbreaks. Here, I will 
discuss the utility of common molecular epidemiological typing methods, 
including whole-genome sequencing for the surveillance of tuberculosis.  
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1.9.1 IS6110 Restriction Fragment Length Polymorphism 
The classification based in the detection of number and position of 
fragments (generated by restriction enzyme PvuII) of the highly conserved 
mobile genetic element, IS6110 that can get inserted anywhere in the M. 
tuberculosis genome forms the basis of the first molecular typing method of 
M. tuberculosis, IS6110 Restriction Fragment Length Polymorphism (RFLP) 
(van Embden et al., 1993). The bands of the fragments are compared with 
the reference fingerprint to standardise the observation across different 
laboratories (Supply, 2015). This method has been useful in outbreak 
investigation (van Soolingen et al., 1999), cross-contamination detection in 
the laboratory (Van Duin et al., 1998) and differentiating exogenous 
reinfection versus endogenous reactivation (Small et al., 1993). Moreover, 
IS6110 RFLP is applicable to the retrospective analyses as it requires the 
growth of mycobacteria in a growth medium (Supply, 2015). Other 
limitations include poor standardization due to the complex genome of M. 
tuberculosis (Supply, 2015), bias due to the variable number of inserts 
(Mazars et al., 2001) or potential absence of IS6110 copies (Dale, et 
al.,1999) and technical demands (Cannas et al., 2016).  
 
1.9.2 Spacer Oligotyping (Spoligotyping) 
Spoligotyping is a PCR based hybridization technique that detects the 
presence or absence of spacer sequences within direct repeat locus (a 
member of clustered, interspaced short palindromic repeat loci within a 
bacterial family) of M. tuberculosis (Kamerbeek et al., 1997). The direct 
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repeat locus is amplified and hybridised using a reverse line technique to 
generate 43-bit barcode (indicating presence or absence of spacer) which 
is compared with the 43 unique spacer references in M. tuberculosis 
(Kamerbeek et al., 1997). The data are generated as a binary code or an 
octal designation and is classified into clade and phylogenetic group using 
the SITVIT database (Demay et al., 2012). This is a cost-effective method 
that can identify different lineages of M. tuberculosis (Supply, 2015). 
However, similarity in the patterns among distantly related sub-strains leads 
to poor resolution of the method, for example, members of Beijing strains 
are grouped as the same spoligotype (Kremer et al., 2004). In addition, the 
phylogenetic inference based in spoligotype pattern may be unclear due to 
homoplasy (Comas et al., 2009). Therefore, spoligotyping is not 
recommended to establish epidemiological links between cases, particularly 
during outbreak investigations (Barnes & Cave, 2003). 
 
1.9.3 Mycobacterial Interspersed Repetitive Unit (MIRU) Variable 
Number Tandem Repeat (VNTR) 
The MIRU-VNTR is based on the amplification technique that uses primers 
specific to flanking regions to multiply tandem repeat sequences followed 
by characterization of M. tuberculosis depending upon the number of 
repeats in each region indicated by the size of amplicons (Supply et al., 
2006). The information is deduced as a globally standardised code 
containing 24-number types which can be analysed (for a phylogenetic 
relationship, genotype and lineage prediction) using the open source 
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database MIRU-VNTRplus (Weniger et al., 2010). This method identifies 
clusters of cases and ongoing TB transmission based on the similarity of 
MIRU-VNTR alleles distributed over 24 loci (Allix-Beguec et al., 2014; 
Savine et al., 2002; Supply et al., 2006). The stability of MIRU-VNTRs 
allows the monitoring of chronic cases over a period of time (Savine et al., 
2002).  Furthermore, the detection of two alleles in two or more MIRU-VNTR 
loci in an isolate indicates potential contamination or mixed infection (Allix, 
Supply, & Fauville-Dufaux, 2004). In terms of resolution, MIRU-VNTR 
possesses more discriminatory power than spoligotyping and is less prone 
to the effect of homoplasy (Cardoso et al., 2011; Wirth et al., 2008). 
McLernon and colleagues recommend the better performance of MIRU-
VNTR and spoligotyping collectively as compared to MIRU-VNTR alone 
(McLernon et al., 2010). However, MIRU-VNTR does not offer a distinction 
between closely related members of the M. tuberculosis Beijing family 
(Roetzer et al., 2011). Furthermore, the resolution of VNTR typing is 
compromised while investigating an established epidemiological link 
(confirmed and presumed), (de Beer et al., 2013).  
A common limitation of the above-mentioned methods is their inability to 
detect variations in the regions other than the small targeted segments 
within the whole-genome of M. tuberculosis. It is plausible that variations 
can independently occur in other areas of the genome leading to increased 
genetic distances between the isolates (Supply, 2015). In addition, these 
techniques offer poor evidence to the measurement of inter-species and 
intra-species evolutionary distances between the M. tuberculosis isolates 
(Filliol et al., 2006). 
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1.9.4 Whole-Genome Sequencing  
Whole-genome sequencing allows the examination of the entire region of a 
genome and facilitates in detecting the variations of possible 
epidemiological importance (Koser et al., 2012). Single nucleotide 
polymorphism (SNP) in M. tuberculosis genome occurs once in every 3kb 
of DNA sequence but is the most common form of genetic variation besides 
insertions/deletions events (Comas et al., 2010). Therefore, SNP based 
typing can potentially represent a “gold standard” method for molecular 
typing of M. tuberculosis (Filliol et al., 2006). The genome of M. tuberculosis 
is highly conserved which is evidenced by the presence of small number of 
SNPs between the reference H37Rv and clinical CDC1551 strain (n=1075) 
(Fleischmann et al., 2002) and is characterized by high clonal population 
structure (Liu et al., 2006). The availability of molecular clock data based in 
SNP analyses indicating the emergence of 0.3 to 0.5 SNPs per genome per 
year has allowed the prediction of epidemiological links between the cases 
(Bryant et al., 2013; Roetzer et al., 2013; Walker, et al., 2013). Furthermore, 
a cut-off of ≤5 SNPs between the isolates has been increasingly used to 
define the TB transmission network (Gautam et al., 2018; Walker et al., 
2013). However, this should be interpreted in relation to available 
epidemiological data as SNP differences may be affected by factors 
including- sampling time, the incidence of TB and genetic similarities 
between the strains in a geographical area (Hatherell et al., 2016; Migliori 
et al., 2008). The lesser likelihood of SNPs to converge adds additional 
advantage over spoligotyping and MIRU-VNTR in analysing the 
phylogenetic relationship between the closely related isolates (Schork, 
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Fallin, & Lanchbury, 2000). Jajou et al. compared WGS and MIRU-VNTR to 
identify clustered cases and found that WGS is approximately two times 
more effective than the later in identifying epidemiologically related cases 
(57% versus 31% respectively) (Jajou et al., 2018). 
The WGS based transmission tracking of TB in both high (Bjorn-Mortensen 
et al., 2016) and low burden countries (Gurjav et al., 2016) have been 
documented. This has also been used to detect mixed TB infections (Gan 
et al., 2016; Sobkowiak et al., 2018) and determine microevolution (Kato-
Maeda et al., 2013), both at inter and intra-patient level (Pérez-Lago et al., 
2014). Whole-genome sequencing identified identical MIRU-VNTR 
genotypes which along with the analyses of patient’s social networks 
detected the presence of a common progenitor during a TB outbreak that 
existed before the onset of transmission (Gardy et al., 2011). This outbreak 
was further related to a social event of the use of crack cocaine (Gardy et 
al., 2011). Furthermore, WGS allows to analyse the functional genomics of 
M. tuberculosis, for example, Colangeli and colleagues analysed the whole-
genome of M. tuberculosis to report the growth characteristics and 
acquisition of drug resistance determining polymorphisms during the latent 
phase of infection (Colangeli et al., 2014). The application of WGS further 
extends in predicting M. tuberculosis drug susceptibility (Walker et al., 
2015), infer phylogenetic relationships (Gautam et al., 2018), evolutionary 
history (Wollenberg et al., 2017) classify strains into lineages and sub-
lineages (Schleusener et al., 2017) and the development of TB diagnostic 
tools (Manson et al., 2017).  
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1.10 Concluding Remarks for the Literature Review and Questions for 
the Present Thesis 
Tuberculosis is a major global health crisis, especially in low income 
countries, but poses a significant threat in specific population groups in 
developed nations, for example, immigrants and socio-economically 
disadvantaged communities. Australia has endorsed the WHO’s Global 
strategy and targets for TB prevention, care and control after 2015. To 
achieve the goal of reducing TB incidence and mortality by 90% and 95% 
respectively by 2035, a drop by approximately 98% is required in the current 
annual TB incidence rate in Australia. In terms of diagnostics, the available 
TB detection and epidemiological typing methods pose limitations in terms 
of their sensitivity, specificity or methods restricted to specifically analyse a 
particular gene locus. Whole-genome sequencing is being increasingly 
developed as a tool to collectively diagnose and perform functional and 
epidemiological genotyping M. tuberculosis.  
Thus, the aims of my thesis were designed to utilize whole-genome 
sequencing to explore the genome of M. tuberculosis and further implement 
the technology to study the molecular epidemiology of TB. The aims are 
summarized as; 
1. To apply whole-genome sequencing as a tool for functional 
genotyping of an outbreak strain of M. tuberculosis. 
2. To apply whole-genome sequencing as a tool to study the 
molecular epidemiology of TB in Tasmania.  
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3. To trace the origin and track the transmission of the first case of 
multi-drug resistant M. tuberculosis detected in Tasmania. 
 
1.11 Hypothesis 
The hypothesis for the genomic study of New Zealand TB outbreak 
“Rangipo” strain relied on the existing report of their high transmissibility. I 
hypothesized that the genome of Rangipo strain contains additional features 
that can potentially be related to its increased virulence. In addition to the 
functional analyses of M. tuberculosis “Rangipo” genome, I hypothesized 
that WGS can be applied for epidemiological typing of tuberculosis in a low 
TB burden setting. The availability of genome sequencing facility at the 
University of Tasmania and bacterial samples from institutions in Australia 
and overseas allowed me to test my thesis hypothesis for the present thesis.  
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Chapter 2 
Method: Whole-Genome Sequencing and Data Analyses  
 
2.1 Introduction 
Using Sanger sequencing, the Human Genome Project cost approximately 
USD $2.7 billion and took 13 years to produce the first human genome 
sequence (International Human Genome Sequencing Consortium 2004; 
Gyles, 2008). Today, a human genome can be sequenced in a matter of 
days for less than USD $1,500 on a single next-generation sequencing 
(NGS) machine (Wetterstrand, 2018). This change in throughput and the 
per-base cost has transformed the use of DNA sequencing in biomedical 
research and is being translated into an expanding number of ways into 
medicine. NGS is increasingly been applied to understanding and managing 
infectious diseases. This includes the sequencing of microbial genomes for 
the purposes of laboratory identification of infectious agents (Lecuit & Eloit, 
2014), detection of antibiotic resistance markers (Walker et al., 2015), and 
the public health surveillance of epidemiological clusters and outbreaks 
(Harris et al., 2013). Examples include its deployment in public health 
surveillance and control of community cases of Escherichia coli (Grad et al., 
2012), Campylobacter jejuni (Llarena, Taboada, & Rossi, 2017), Legionella 
pneumophila (Reuter et al., 2013) and Mycobacterium tuberculosis 
(Gautam et al., 2018) disease, or global and regional epidemics caused by 
influenza (McGinnis, Laplante, Shudt, & George, 2016), Ebola (Park et al., 
2015), and Zika (Metsky et al., 2017) viruses. It has also been utilised to 
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track the source and spread of healthcare-associated infections caused by 
Staphylococcus aureus (Köser et al., 2012), Pseudomonas aeruginosa 
(Davis et al., 2015), Acinetobacter baumannii (Halachev et al., 2014), and 
Enterococcus faecium (Leong et al., 2018) to guide the infection prevention 
and control strategies in health care settings. 
In addition to whole-genome sequencing (WGS), whole exome, 
transcriptome (RNA-Seq), bisulphite methylome, and metagenomic 
sequencing, NGS can be directed to the detection of specific genes or 
mutations associated with human disease through targeted-panel amplicon 
screening. However, barriers remain with regard to establishing NGS in a 
laboratory for the first time and this hinders its uptake in clinical microbiology 
and other settings. One of these challenges is the lack of a simplified step-
by-step protocol that can be picked up by laboratory personnel with no prior 
training or experience in NGS and used to generate reliable, high quality 
sequence data. Illumina dye-sequencing is currently considered the gold 
standard internationally in terms of the read depth and base-calling 
accuracy, genome coverage, scalability, and the range of sequencing 
applications it delivers.  
In this work, I produced an easy-to-follow, step-by-step NGS protocol with 
consistent genome coverage and average read depth that was applicable 
to a range of bacterial pathogens i.e. Gram-positive vancomycin-resistant 
Enterococcus faecium, Gram-negative non-typeable Haemophilus 
influenzae, and acid-fast high-GC content Mycobacterium tuberculosis. This 
protocol can be used to generate the Illumina-based WGS data for clinical 
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isolates of bacterial pathogens of importance to human health. This 
laboratory procedure generated Fastq reads from the sequencer within 
three days of start. I modified a number of the DNA extraction steps to obtain 
a sufficient quantity of contamination free template. Similarly, I replaced 
library normalization plates and Nextera XT tagment Amplicon plates with 
conventional PCR tubes which may represent a cost-effective alternative. 
In addition, I recommended the use of equal DNA concentrations of each 
library during library normalization to ensure better coverage and minimize 
bias.  
 
2.2 Materials and Method 
2.2.1 Bacterial DNA Extraction 
For next generation sequencing, contaminant-free, high-molecular weight 
DNA with an absorbance (260nm/280nm) ratio (1.8 to 2.0) is considered to 
be a high-quality template DNA (Healey et al., 2014). For DNA extraction, 
bacteria grown in liquid culture media were pelleted (8,000 g for 8 minutes) 
in a sterile microfuge tube. The pellet was resuspended in 600 µL 
phosphate-buffered saline (PBS) until the absorbance at 600 nm (A600) 
was between 1.0 and 2.0. The cell suspension was lysed by adding 30 µL 
lysozyme (50 mg/mL) (Muramidase, VWR Chemicals, Radnor, PA, USA), 
vortexed, and incubated at 37 ⁰C for 1 hour. The DNeasy® Blood and Tissue 
Kit (Qiagen, Hilden, Germany) Quick-start protocol with modifications was 
then used for the extraction of bacterial DNA from the lysed cell suspension. 
To 200 µL lysate, 20 µL proteinase K and 200 µL buffer AL was added and 
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mixed by vortexing. 200 µL 100% ethanol was added to the suspension and 
vortexed. The 620 µL mixture was then transferred to a DNeasy mini spin 
column placed in a 2mL collection tube and centrifuged at 8,000 g for 1 
minute. The spin column was placed in a new collection tube, 500 µL buffer 
AW1 added, and centrifuged for 1 minute at 8,000 g. The spin column was 
again placed in a new collection tube, 500 µL buffer AW2 added, and 
centrifuged at 20,000 g for 3 minutes. The spin column was finally 
transferred to a 1.5mL sterile microfuge tube and added with 100 µL buffer 
AE, incubated for 1 minute at room temperature, and centrifuged at 8,000 g 
for 1 minute to obtain bacterial DNA. The eluted DNA (100 µL) was treated 
with 2 µL RNAse (100 mg/mL) (Qiagen, Hilden, Germany) and incubated at 
room temperature for 1 hour. The High Pure PCR Template Preparation Kit 
(Roche, Basel, Switzerland) was used to purify the RNAse-treated DNA.  A 
modification was made to the manufacturer’s protocol in which I performed 
only four DNA spin-wash steps instead of 9 recommended steps. Initially, 
100 µL of binding buffer was added to RNAse treated DNA and incubated 
at 70 ⁰C for 10 minutes and then mixed with 50 µL of isopropanol. The 
content was transferred to a Roche spin column and spun at 8,000g for 1 
minute. The flow through was discarded and the spin column was inserted 
into a new collection tube. A single wash step was performed by adding 
500µL wash buffer and spun at 8,000 g for 1 minute. The flow through was 
discarded and the spin column was inserted into a new collection tube. A 
final spin (8,000 g for 1 minute) was performed to get rid of excess wash 
buffer from the spin column. Finally, the spin column was inserted into a 
1.5mL sterile microfuge tube and 50µL of pre-heated elution buffer (70 ⁰C) 
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were added. The tube was spun at 8,000 g for 1 minute to elute the purified 
DNA for next generation sequencing.  
 
2.2.2 Quantification of Bacterial Genomic DNA 
The use of an accurate concentration of DNA is crucial for bacterial DNA 
genomic library preparation. To standardize the concentration of DNA, I 
used the Qubit dsDNA (double-stranded DNA) HS (high sensitivity) 
Quantification Kit (Life Technologies, Carlsbad, CA, USA) to quantify the 
amount of DNA. For Qubit assay, 10 µL of standards and 2 µL of sample 
were added in separate Qubit assay tubes (Life technologies, USA) 
containing 190 µL and 198 µL of pico green working solution respectively. 
The Qubit reading was taken after vortexing the mixture for 3 seconds 
followed by its incubation at room temperature for 2 minutes. The DNA 
concentration of each sample was adjusted to 0.2 ng/µL after dilution with 
a required volume of ultrapure™ DNAse/RNAse free distilled water 
(Invitrogen). 
 
2.2.3 Tagmentation and PCR Amplification of Bacterial Genomic DNA 
At this stage, the input DNA is simultaneously fragmented and adapter 
sequences are added for the subsequent PCR amplification step. This 
section provides details of the processes involved to fragment and add 
adapter sequences to template DNA using single tube Nextera XT 
Tagmentation and to generate multiplexed sequencing libraries. I followed 
the Nextera XT DNA sample preparation guide (Illumina, 2012) with in-
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house modifications in terms of consumables and the volume of specific 
sample/reagents. I replaced the use of 96-Ill TYC plate with 0.2 mL thin wall 
clear, flat capped PCR tubes (Fisher scientific, Australia) throughout the 
method. I also replaced the multichannel pipettes and the high-speed micro 
plate shaker with single channel pipettes and a bench top centrifuge, 
respectively. 
  
2.2.3.1 Nextera XT Tagment Amplicon (NTA) Construction  
To 2.5 µL (0.2 ng/µL) input DNA in a PCR tube, I added 5 µL tagmentation 
DNA buffer and 2.5 µL amplification tagmentation mix. The content was 
briefly vortexed and then transferred to the Applied Biosystems® Veriti 96-
Ill thermal cycler (Thermo Fisher Scientific, Foster City, CA, USA) and 
programmed for a step at 55 ⁰C for 5 minutes with heated lid, followed by a 
hold at 10 ⁰C for a volume of 10 µL.  
 
2.2.3.2 Neutralization of NTA 
Immediately after reaching the hold temperature of 10 ⁰C in the above step, 
NTA was neutralized by the addition of 2.5 µL neutralization tagmentation 
buffer and incubation at room temperature for 5 minutes.  
 
2.2.3.3 PCR Amplification 
In this stage, the tagmented, neutralized DNA obtained above was amplified 
using index primers 1 and 2 (Nextera® XT index kit) for cluster formation. 
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For amplification, 7.5 µL Nextera® PCR master mix and 2.5 µL of index 
primers 1 and 2 each were added to the tube containing neutralized NTA. 
The index primers were carefully selected, and labels noted for their use in 
the later stage of sample sheet preparation during MiSeq WGS. Primer 
combinations, S502 with N705 /706 and S503 with N701/702 were avoided 
due to the absence of certain channel colours during whole-genome 
sequencing (Illumina, 2012). The content was gently pipetted and quickly 
spun before amplification step which was performed with a Applied 
Biosystems® Veriti 96-well thermal cycler (Thermo Fisher Scientific, USA) 
programmed for a working volume of 25 µL with the following settings: 
heated lid, initial cycle at 72 ⁰C for 3 minutes followed by 95 ⁰C for 30 
seconds and 12 cycles of (95 ⁰C for 10 seconds, 55 ⁰C for 30 seconds and 
72 ⁰C for 30 seconds) with a final run at 72 ⁰C for 5 minutes followed by a 
hold temperature of 10 ⁰C. The amplified, tagmented library was stored at 2 
to 4 ⁰C overnight for PCR clean-up the next day.  
 
2.2.4 Cleaning up the PCR Product 
This stage involves cleaning up the amplified PCR product (DNA library) 
using Agencourt® AMPure XP beads (Beckman Coulter, Brea, CA, USA). 
The use of magnetic beads allows the selection of appropriately sized library 
fragments and the removal of very short fragments. For PCR product clean 
up, AMPure XP beads were brought to room temperature (for 20 minutes) 
and 80% (v/v) ethanol and 0.2 molar NaOH (40mg NaOH in 5mL distilled 
water) prepared. To 22.5 µL of PCR product, 11.25 µL of vortexed (30 
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seconds) AMPure XP beads were added and mixed by pipetting (10 times). 
The recommended ratio of PCR product and AMPure XP beads is 1:1.6 but 
I modified the ratio to 1:2. I found this increase in total volume allowed the 
beads to reach the magnetic ring without affecting the recovery. After 
incubation at room temperature for 5 minutes, the tubes were placed on a 
magnetic stand for 2 minutes. While leaving the PCR tubes on the magnetic 
stand, the supernatant was carefully aspirated and discarded (without 
aspirating the beads). To the tubes, 100 µL of 80% ethanol was added 
(beads were not resuspended) and left to stand in the magnetic stand for 
30 seconds and the supernatant carefully removed. 100 µL of 80% ethanol 
was added again. After removing all of the ethanol by pipetting, the tubes 
containing the beads were removed from the magnetic stand and allowed 
to air dry in a tube stand for approximately 5 minutes while visually checking 
for cracks as over drying the beads will significantly reduce elution 
efficiency. Once the tubes were dried, 26.15 µL of resuspension buffer was 
added with gentle pipetting 20 times to mix. The tubes were incubated at 
room temperature for 2 minutes and then placed again on a magnetic stand 
for 2 minutes (until the supernatant cleared), followed by transfer of the 
supernatant to new PCR tubes. Although the final supernatant could be 
stored at -15 to -20°C for up to 1 week, I recommend proceeding to library 
normalization immediately. 
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2.2.5 Library Normalization 
The cleaned-up PCR product obtained from different samples may not 
contain an equal concentration of DNA. A pool of accurate input DNA 
quantity results in more even genome coverage with minimal bias and 
ensures consistent and reproducible results downstream (Doyle, 2015). For 
minimally concentrated DNA template, an increased number of PCR cycles 
to obtain a high amount of PCR product is contraindicated as it impairs 
sequence heterogeneity and leads to poorer sequence quality (Robin et al., 
2016). In contrast, for a sample with a high amount of PCR product, dilution 
is recommended as a decreased amount of template DNA may increase the 
ratio of duplicate reads and also increase coverage in low GC regions 
(Parkinson et al., 2012). I, therefore, prepared a pool of DNA from different 
samples such that the concentration of each was represented equally for 
the sequencing run.  
The Qubit DNA quantification method as described previously was used to 
determine library concentration in each sample. The sample with the lowest 
DNA concentration was used in a volume of 10µL as the reference to 
prepare a library pool using the formula: 
Volume required (V2) = Concentration original (S1) x Volume total (V1 = 10 
µL) divided by Concentration required (S2).  
In this modified step, I normalised the library by using LNS1 (Library 
Normalisation Storage Buffer 1) only. To X µL of library pool, X µL of freshly 
prepared 0.2molar NaOH (final concentration 0.1 molar) was added and 
incubated for 5 minutes at room temperature. To the NaOH treated 
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suspension, an equal volume (2X µL) of LNS1 was added from the 
Nextera® XT library preparation kit. From this, a 1:1000 dilution of (1 µL of 
sample added to 1000 µL of ultrapure distilled water) was prepared for the 
quantitative PCR (qPCR) run.  
 
2.2.6 Quantification of the NaOH Treated Pooled Library 
To check the concentration of pooled library, I used KAPA library 
quantification kit Illumina® (No ROX) for quantitative PCR on a Corbett 
Rotor-Gene 6000 real-time thermocycler (Corbett Research, Rotor-gene) 
using the following set up: a hot start run at 95⁰C for 10 minutes followed by 
40 cycles of (95⁰C for 10 seconds and 60⁰C for 30 seconds). A set of six 
DNA standards (with concentrations ranging from 20 picomolar (pM) to 
0.0002 pM), three sets of negative control (ultrapure distilled water), and 
three sets of the DNA library were included in the qPCR run.  
Following the completion of the qPCR, the concentration of DNA in the 
pooled library was determined by the standard curve method and calculated 
in pM concentration per tube. To calculate the original concentration of the 
pooled library I applied the formula: 
Average sample concentration (in pM) * insert size standards (452 base 
pairs) * dilution factor (1000) divided by insert size of the pooled library (500 
base pairs) 
The concentration and size profile of the library is dependent on the amount 
of input DNA. The average fragment size ranged from 250 base pairs to 1.5 
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Kb in length and an average library fragment size of 500 base pairs was 
used for the calculation (Illumina, 2014). 
This value obtained from the calculation represented the concentration of 
DNA in the pooled library and was used to estimate the dilution factor 
required to achieve a final library concentration of 15 pM in a 600 µL volume 
(using buffer HT as a diluent). 
For example, for a qPCR determined concentration of 2.36 pM in a 1:1000 
dilution of the pooled library, the library DNA concentration is determined as 
follows 
 (2.36 pM * 452 base pairs * 1000) /500 base pairs = 2135.25 pM (library 
concentration) 
To calculate the volume of the pooled library to dispense onto the MiSeq 
reagent cartridge, the following formula is used: 
Volume required = (Concentration required * Volume total) divided by 
Concentration original 
i.e.           = (15pM * 600 µL) / 2135.25 pM 
          = 4.22 µL  
Therefore, 4.22 µL is added to 595.78 µL of HT buffer to produce a final 
concentration of 15 pM, in a final volume of 600 µL. The diluted library is 
then ready to be heat denatured and loaded into the MiSeq reagent 
cartridge. 
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2.2.7 Preparing Pooled Library for Loading onto MiSeq 
The pooled amplified library (PAL) was thawed at room temperature and 
mixed by pipetting up and down (5 times) and briefly centrifuged. Based on 
the library concentration example above, I then transferred 595.78 µL of HT 
buffer to a 1.5mL diluted amplified library (DAL) tube containing 4.22 µL PAL 
and mixed using a pipette (5 times). The DAL tube was then vortexed at top 
speed, centrifuged briefly, and incubated exactly for 2 minutes at 96 ± 2 ⁰C. 
The DAL tube was then immediately transferred to ice for at least 5 minutes. 
Prior to commencing the whole-genome sequencing process, the Illumina 
MiSeq sequencer was put through a short wash cycle to avoid cross-
contamination of the DAL from the previous usage. According to the 
manufacturer’s protocol, the MiSeq reagent cartridge was thawed at room 
temperature. The Illumina Experiment Manager was used to generate a 
MiSeq sample sheet with the following configuration:  
Generate FASTQ workflow; FASTQ Only application; NexteraXT assay; 
151 insert reads; assignment of the samples with a unique identifier and 
index-pair combination.  
The entire 600 µL of DAL was finally loaded onto the MiSeq reagent 
cartridge. Following the setup procedure of the Illumina Experiment 
Manager in which the flow cell was rinsed with MilliQ water and soak dried, 
the reagent buffer and the DAL loaded MiSeq reagent cartridge was 
inserted into MiSeq instrument for sequencing to commence. The raw Fastq 
sequence reads from whole-genome sequencing were stored on the local 
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computer as well as on the Illumina BaseSpace server 
(https://basespace.illumina.com/) for further analysis. 
 54 
 
 
 
Figure 2.1. Schematic diagram showing processes involved in generating whole-genome sequence data of M. tuberculosis.
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2.3 Bioinformatics Analysis 
2.3.1 Data Analyses Tools  
The selection of bioinformatics software for the analysis of WGS data may 
be determined according to the objective of the study. Here, I used 
Geneious 9.1.8 (Biomatters Ltd.) (Kearse et al., 2012), a desktop software 
to map, find variants, locate differentially encoded genes and build a 
phylogenetic tree using the available plugins (Supplement 1). In addition, I 
used Galaxy Australia (Afgan et al., 2015) based tools, for example, FastQC 
(Andrews, 2010), Burrows-Wheeler Aligner (Li & Durbin, 2010), SAM-tools 
and SnpEff (Li et al., 2009) to examine the sequenced data. The data were 
also analysed and by a collaborator at Trinity College Dublin, Ireland. A 
consensus was made by comparing the results obtained by myself and the 
collaborator before reaching to a final conclusion and submission for the 
publications. The open source databases, for example, TGS-TB (Sekizuka 
et al., 2015), PhyResSe (Feuerriegel et al., 2015), COG (Tatusov et al., 
2000), BLAST (Altschul et al., 1997) and KEGG (Kanehisa & Goto, 2000) 
were used to further analyse the whole-genome sequence data of tubercle 
bacilli. These databases enabled the acquisition of information on bacterial 
pathogens that include genotype and phylogeny and antibiotic-resistance 
mutations. For example, M. tuberculosis complex raw fastq.gz files 
uploaded to the TGS-TB database (Sekizuka et al., 2015) produced results 
in terms of presence of mutations determining drug resistance, in silico 
spoligotyping, identification of lineage type, and phylogenetic tree 
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building with respect to the available strains in the database. This database 
also enabled the detection of IS6110 insertion sites, and 43 customized loci 
for variable number tandem repeat (VNTR). A list of bioinformatics tools and 
databases used for the analyses of whole-genome sequence data in the 
thesis is summarised in table 3. 
This method of generating whole-genome sequence data of bacteria 
including M. tuberculosis was based on the manufacturer’s instructions 
(Illumina, Inc. 2012). Modifications were done in terms of the usage of 
consumables and library normalization step to maximize the quality of 
output data (Gautam et al., 2019a). The proposed method was not 
compared for its sensitivity and accuracy with any published protocol; 
however, we were able to reproduce the protocol for studies involving M. 
tuberculosis and other bacterial pathogens (Gautam et al., 2019; Gautam 
et al., 2018; Gautam, Mac Aogáin, & O’Toole, 2017; Leong et al., 2018; Mac 
Aogáin et al., 2016). 
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Table 3. Bioinformatics tools and databases used across different chapters in the present thesis 
Databases/Tools Purpose Chapters 
Burrows-Wheeler 
aligner 
Mapping 3,4,5 
SAMtools Variant detection 3,4,5 
SnpEff Variant annotation 3,4,5 
SPAdes de novo assembly of contigs 3,4,5 
PhyResSE Drug-resistant mutation detection  3,4,5 
Geneious Trimming, mapping, variant detection, de novo assembly, contigs and consensus sequence 
generation, open reading frame analyses, primer design, phylogenetic tree construction  
3,4,5 
BLASTp Search protein databases 3 
BLASTn Search nucleotide databases 3 
KEGG Identification of a cluster of orthologous groups 3 
PhymL Phylogenetic tree construction 3,4 
TB Profiler Lineage prediction and detection of drug resistant conferring polymorphisms 4,5 
TGS-TB In silico spoligotyping 4 
ABACAS Order assembled contigs 5 
Galaxy Determine the quality of sequenced data using FastQC 3,4,5 
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Chapter 3 
Investigating Virulence Related Genes in an Outbreak Strain of 
Mycobacterium tuberculosis using Whole-Genome Sequencing 
 
3.1 Tuberculosis Outbreak  
Tuberculosis (TB) accounts for approximately five thousand deaths per day. 
The majority (55%) of the total new TB cases in 2017 were reported across 
five countries including India, China, Indonesia, the Philippines and 
Pakistan (in descending order) (World Health Organization, 2018d). 
However, outbreaks of TB can occur in low as well as high TB burden 
countries. For example, M. tuberculosis strain CDC1551 accounted for an 
outbreak of TB during 1994-1996 in two low TB burden (<1 case per year) 
counties (Tennessee and Kentucky) of the USA where 311 out of 429 
contacts of TB patients were detected positive for M. tuberculosis infection 
in a skin test (Valway  et al., 1998). Similarly, an outbreak of TB was 
identified in a high incidence (2901 per 100 ,000 population) Daru island of 
Papua New Guinea where 0.76% of total 16,714 population were diagnosed 
with multi-drug resistant TB (Bainomugisa et al., 2018). The factors 
associated with increased TB transmission may be categorised under 
microbial properties and the hosts’ environmental circumstances. For 
example, the CDC1551 strain is associated with increased virulence 
(Valway et al., 1998) and M. tuberculosis Beijing strain is related to their 
higher transmission rate (Iwamoto et al., 2009; Yang et al., 2012). The host 
environmental factors favouring transmission include household 
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overcrowding (Waziri et al., 2014), homelessness, co-infection with HIV, 
increased median infectious period (Powell et al., 2017), mental illness and 
substance abuse (Dobbins et al., 2012).  
Although a prolonged period of latency after M. tuberculosis exposure may 
affect the reliability to describe an event of TB outbreak, the definition for 
TB outbreak been established to prioritise the resource allocation in such 
circumstances (Denholm et al., 2016). The description of TB outbreak varies 
with the local situation. For example, the CDC criteria to identify a TB 
outbreak is primarily based on the surveillance data where notifications of a 
higher number of TB cases than predicted, detection of TB in two or more 
connected cases during contact investigation, an established link between 
two or more cases diagnosed within a year that may not have been identified 
during contact investigation and genotypic evidence of transmission that 
was not detected during contact investigation during the preceding two 
years is flagged as an outbreak of TB (Freimanis e al., 2007). Furthermore, 
the outbreak is confirmed when control measures are unable to disrupt the 
ongoing TB transmission and when TB investigation programs require 
additional assistance (Freimanis et al., 2007). The Communicable Diseases 
Intelligence (CDI) publication of the Australian Department of Health 
provides definitions for a cluster of TB cases, a probable cluster, a possible 
cluster, and an outbreak of TB (Denholm et al., 2016). Any two or more 
active cases of TB with known epidemiological links and related to the same 
genotype of M. tuberculosis are defined as TB cluster cases (Denholm et 
al., 2016). The outbreak of TB is described when active cases of TB are 
detected in three or more members (where at least two members transmit 
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disease) with an epidemiological and microbial genotypic linkage supporting 
evidence of serial transmission (Denholm et al., 2016).  
 
3.2 Investigating the Genome of an Outbreak Strain of M. tuberculosis 
in New Zealand 
 
3.2.1 Tuberculosis in New Zealand  
New Zealand is a low TB incidence country with 310 cases reported among 
4.7 million people in 2017 (World Health Organization, 2018h). The majority 
of TB cases in New Zealand have been detected among individuals 
belonging to Middle Eastern/Latin American/African ethnic groups (22.1 per 
100,000 population) and residents of socio-economically disadvantaged 
locations (Institute of Environmental Science and Research Ltd, 2015). 
Individuals born overseas or living with people not born in New Zealand 
were the most common risk factors associated with TB (Institute of 
Environmental Science and Research Ltd, 2015). A discrete distribution of 
cases was noted across different district health boards in New Zealand 
where the national rate of TB incidence is significantly affected by events of 
TB outbreak. For example, two outbreaks of TB added 14 new cases to the 
national notification data in 2014 (Institute of Environmental Science and 
Research Ltd, 2015). 
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3.2.2 Mycobacterium tuberculosis “Rangipo” Strain Outbreak in New 
Zealand   
An analysis of a TB outbreak that occurred between 1996 and mid 2000 in 
New Zealand identified a mother of the newly born child as an index case 
(De Zoysa et al., 2001). Based on the IS6110 restriction-fragment length 
polymorphism DNA typing, 43 out of 61 TB cases were identified as 
members of the same TB outbreak that occurred across eight districts over 
a period of three and half years (De Zoysa et al., 2001). The remaining 18 
cases were epidemiologically related to the outbreak (De Zoysa et al., 
2001). A majority (86.9%) of these cases were detected in the indigenous 
Māori population (De Zoysa et al., 2001). One of the patients related to the 
outbreak served his sentence in the Tongariro/Rangipo prison in 1998 which 
led to the derivation of the strains name, “Rangipo” (McElnay, Thornley, & 
Armstrong, 2004). In 2002, an outbreak of TB due to Rangipo strain 
involving 19 active cases was identified in the Hawke’s Bay area on New 
Zealand’s North Island (McElnay, Thornley, & Armstrong, 2004). The high 
transmissibility of the Rangipo strain was demonstrated by the detection of 
active TB in 16.4% and latent TB in 20% of close contacts (McElnay, 
Thornley, & Armstrong, 2004). This particular strain constituted a major 
proportion of TB cases in 13 out of 18 district health boards between 2003 
and 2007 in New Zealand (Sexton, Petera, & Pandey, 2008). Based on the 
large sequence polymorphism and SNP analyses, the Rangipo strain is 
phylogenetically classified as the Euro-American lineage 4 M. tuberculosis 
(Yen et al., 2013). Although the high infective potential of the Rangipo strain 
 62 
 
has been proposed previously (McElnay, Thornley, & Armstrong, 2004), 
experimental evidence to support this claim is limited.  
In this study, I performed whole-genome sequencing of M. tuberculosis 
Rangipo strain to explore the virulence related properties encoded in its 
genome. This chapter is published  online (Gautam et al., 2017a) and can 
be accessed here: https://doi.org/10.1080/23744235.2017.1330553 
 
3.2.3 Materials and Methods  
 
3.2.3.1 Culture and MIRU Typing of the Rangipo Strains 
The Rangipo isolates were grown in Mycobacteria Growth Indicator Tube 
(MGIT) media at LabPLUS Limited, Auckland City Hospital and 
Mycobacterial Interspersed Repetitive Unit (MIRU) 24-loci typing was 
performed as described previously (Cole et al., 1998). The MIRU clusters 
were confirmed when the isolates possessed the same number of copies 
across all the loci. Eight isolates displayed a common 24-loci MIRU profile 
(233325153324 341444223362) while the ninth isolate (sample 356) varied 
in one of the loci. Whole-genome sequencing was performed on purified 
DNA extracts from nine Rangipo isolates as explained in Chapter 2 
generating paired-end Fastq reads.  
 
3.2.3.2 Bioinformatics Data Analyses  
The Fastq sequence data files were analysed using the Geneious R9.0 
software suite (Kearse et al., 2012). The reads were trimmed with an error 
probability limit set at 0.05 to remove the Illumina adapter sequences. 
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Initially, the sequences were mapped against the reference strain H37Rv 
(accession number NC_000962.3), a publicly available and widely used 
annotated reference genome of M. tuberculosis (Cole et al., 1998). For 
mapping, I used random multiple base match set at a maximum variant p-
value of 10-6 when exceeding 65% bias. Single-locus variations (SLVs) and 
insertions and deletions (indels) were identified using the BWA/SAMtools 
mapping approach as described previously (Mac Aogain et al., 2016). 
Briefly, I analysed regions with a minimum read depth of 20 and a minimum 
variant frequency of 95%. This allowed us to detect SLVs in Rangipo strains 
with respect to the reference genome, H37Rv. The genes containing non-
synonymous SLVs were categorised into the different cluster of orthologous 
groups (COGs) based on their known or predicted function. In addition, the 
literature was searched to relate the role of these mutations in M. 
tuberculosis virulence (Forrellad et al., 2013).  
After analysing the SLVs, I was interested to examine if the Rangipo strain 
possessed additional genes that are related to the physiology or 
pathogenesis of M. tuberculosis. It is apparent that not all the sequences in 
the test strain align with the reference genome during the process of 
genome assembly. To identify genes that were present in the Rangipo strain 
but absent in the M. tuberculosis reference strain H37Rv, I took the 
unmapped reads obtained after mapping with H37Rv. These unmapped 
reads were de-novo assembled to generate a consensus sequence. From 
the consensus sequence, open reading frames (ORFs) of at least 150 
nucleotides with start codons ATG, TTG or CTG and standard genetic code 
were produced. I selected interior ORFs for the analyses assuming that start 
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and/or stop codons may be positioned away from the minimum length of 
ORF. The analyses of ORFs in terms of their predicted protein product 
present in M. tuberculosis was done using the BLASTP database 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990) where the 
search was targeted for non-redundant protein sequences. This 
represented gene insertions in Rangipo strain relative to H37Rv. 
Furthermore, to identify the orthologues of additional copies of Rangipo 
genes (that were absent in H37Rv) in other strains of M. tuberculosis, a cut-
off of ≥ 98 % in terms of subject and query sequence match was used.  
To infer the phylogenetic relationship between the isolates, the consensus 
sequence of each Rangipo genome generated after mapping with M. 
tuberculosis reference strain H37Rv was used. The generalised time 
reversible (GTR) substitution model was used to derive a maximum 
likelihood (ML) phylogenetic tree using PhyML where 10 starting trees were 
selected and bootstrapping was performed over 100 replicates (Guindon & 
Gascuel, 2003). The PhyML ML algorithm was used to infer the 
phylogenetic relationship between the isolates as it allows us to input 
alignment of nucleotides for the analyses and has been widely used as a 
reliable method to test the biological hypothesis (Guindon et al., 2009; 
Casali et al., 2014). In addition to the nine Rangipo strains, four annotated 
whole-genomes of lineage 4 M. tuberculosis strains, H37Rv (NC_000962), 
CDC1551 (NC_002755), Haarlem (NC_022350), and Erdman 
(NC_020559) were included in the phylogeny construction.  
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3.2.3.3 Description of the Whole-Genome Features of a Rangipo Strain 
and Deposition of the Sequence in Public Databases 
A representative isolate of Rangipo strain (isolate number 494) was mapped 
to the M. tuberculosis strain H37Rv reference genome (accession no. 
NC_000962) using the Burrows-Wheeler Aligner (Li & Durbin, 2010). The 
contigs obtained after mapping were de novo assembled using the SPAdes 
assembler (version 3.7) (Bankevich et al., 2012). The number of variants in 
the Rangipo genome with respect to the H37Rv reference genome was 
obtained using the SAM-tools platform. These variants were then annotated 
using the SnpEff analyses suite (Cingolani et al., 2012). To identify the 
presence of drug resistance determining mutations in the Rangipo strain, 
paired-end raw Fastq files were imported into the publicly available 
PhyResSE database (Feuerriegel et al., 2015). The whole-genome shotgun 
project of an isolate 494 was submitted for deposition at DNA Data Bank of 
Japan (DDBJ), European Nucleotide Archive (ENA) of European Molecular 
Biology Laboratory (EMBL), and the National Institute of Health’s genetic 
sequence database, GenBank and is obtained under accession number 
LXWG00000000. 
 
3.2.4 Results  
 
3.2.4.1 Single Locus Variations in the TB Outbreak ‘Rangipo’ Strain  
A total of 727 single locus variations (SLVs) with respect to the reference 
H37Rv strain were identified across all the nine Rangipo genomes. Of 
these, 700 SLVs were common to all of the Rangipo isolates sequenced. 
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The result is comparable to that of Colangeli and colleagues who reported 
the presence of 747 single nucleotide polymorphisms (SNPs) with respect 
to H37Rv in 10 Rangipo isolates studied (Colangeli et al., 2014). The 
Rangipo common SLVs in this study constituted 386 non-synonymous SLVs 
which were further categorised as missense variants (n=354), frameshift 
mutations (n=21), in-frame insertions (n=4), in-frame deletions (n=2), gains 
in stop codon (n=4) and loss in stop codon (n=1). To identify TB cases 
belonging to the same transmission network, a cut-off of ≤ 5 SNP 
differences between the isolates was used as described previously 
(Nikolayevskyy, Niemann, & Drobniewski, 2016; Walker et al., 2013).  
The number of SNP differences between isolates ranged between 0-19. For 
example, isolates 431 and 356 exhibited no SNP variation while isolates 
547 and 278 were separated by 19 SNPs (Table 4) (Gautam et al., 2017a).  
 
Table 4. Single-locus variation differences between the nine Rangipo 
isolates mapped to the M. tuberculosis reference genome, H37Rv.  
 376 278 431 356 547 22 494 486 467 
376  17 8 8 10 6 6 7 7 
278   11 11 19 15 15 16 16 
431    0 10 6 6 7 7 
356     10 6 6 7 7 
547      8 8 9 9 
22       4 5 5 
494        1 1 
486         0 
467          
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Reproduced with permission from Gautam et al. Infect Dis (Lond). (2017). 
Copyright Informa UK Limited. 
 
3.2.4.2 Functional Classification of SLVs Detected in the Rangipo 
Strain  
Across the 700 Rangipo common SLVs, four coding sequences including 
Rv0872c, Rv1435c, Rv2407 and Rv2823c had in-frame insertions whereas 
in-frame deletions were identified in two coding sequences, Rv3345c and 
Rv0849. Similarly, 4 genes (pstA1 (Rv0930), ipdA (Rv3303), PE35 
(Rv3872) and Rv0851c) gained a stop codon while the polyketide beta-
ketoacyl synthase pks3 gene (Rv1180) lost a stop codon. In addition, 55 
variants were identified in genes encoding members of the PPE and 
PE_PGRS families of proteins. Non-synonymous single locus variants, 
common to all Rangipo genomes sequenced, were detected in 12 genes 
that have been linked to the virulence of M. tuberculosis (Forrellad et al., 
2013). These included SLVs in aceAa, fadD28, kefB, mce1F, mycP1, pckA, 
pepD, phoR, pks15, plcB, pstA1 and pstS1 (Table 5) (Gautam et al., 2017a). 
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Table 5. Non-synonymous single-locus variations detected in the nine Rangipo isolates sequenced in genes related to mycobacterial 
virulence.  
Locus tag Gene Role of the gene in virulence Nucleotide change Amino acid change 
Rv0174 mce1F Growth regulation in murine macrophages 1109T>C Leu370Pro 
Rv0211 pckA Growth regulation in the human monocyte cell line 302A>C Asn101Thr 
Rv0758 phoR Regulation of cell wall hydrophobicity 515C>T Pro172Leu 
Rv0930 pstA1 Resistance to host immunity 913C>T Arg305a 
Rv0934 pstS1 Adhesin binding to macrophages 63_64insA Ala22b 
Rv0983 pepD Stress response protein 1169T>C Leu390Pro 
Rv1915 aceAa Growth regulation in acetate containing medium 26A>C Glu9Ala 
Rv2350c plcB Growth regulation in macrophages 1406T>C Leu469Ser 
Rv2941 fadD28 Virulence attenuation in BALB/c mice 545T>C Val182Ala 
Rv2947c pks15 Interaction with host cells 998T>C Val333Ala 
Rv3236c kefB Bacterial persistence in Guinea pig 962G>T Arg321Leu 
Rv3883c mycP1 Regulation of ESX-1 979C>T Pro327Ser 
aStop gained. bFrameshift variant. 
Reproduced with permission from Gautam et al. Infect Dis (Lond). (2017). Copyright Informa UK Limited. 
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3.2.4.3 Classification of Genes Containing Non-Synonymous Variants 
into Different Cluster of Orthologous Group Categories  
Genes containing non-synonymous variants in the Rangipo strain were 
classified into functional classes of the cluster of orthologous group (COG) 
(Galperin et al., 2015). A total of 411 NS-SLVs were analysed for their 
distribution into different COG categories. This resulted in the classification 
of 156 genes into single COG categories and 11 genes into two COG 
categories with the remaining 219 genes unassigned based on the current 
KEGG database (http://www.genome.jp/kegg/) (Kanehisa et al., 2016). A 
higher proportion (59.5%) of NS-SLVs present in all Rangipo strains were 
detected in genes related to metabolic function categorised as COG groups 
C, E, F, G, H, P, Q, R, S, and I. This was followed by categories D, M, N, O, 
T and V (23.5%) associated with cellular process and signalling. In contrast, 
the lowest numbers of genes were classified under nucleotide transport and 
metabolism COG F (n = 1) and cell motility COG N (n = 2) groups (Table 6) 
(Gautam et al., 2017a). The functional impact of the number of 
polymorphisms in each COG category has not been widely reported. 
However, we can speculate that the higher number of polymorphisms in 
genes related to metabolic function in Rangipo strain may be related to the 
production of mutant enzyme required for their adaptation in the 
surroundings (IIina et al., 2013). Furthermore, a low number of NS-SLVs 
related to M. tuberculosis cellular process and signaling suggests the 
evolutionary pressure in the genes of this category (IIina et al., 2013). Fewer 
numbers of NS-SLVs in COG N and COG V may indicate conserved cell 
surface structure of the Rangipo strain and its non- extremely drug resistant 
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phenotype respectively (IIina et al., 2013). Notably, the number of genes in 
each category should be carefully interpreted as their proportion in the COG 
system more likely impacts the observation in each category. For example, 
a greater number of genes assigned in the C, H and L (102, 123, 81, 
respectively) categories of the COG system.  
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 Table 6. Classification of Rangipo common genes containing non-
synonymous single-locus variations into different clusters of orthologous 
groups (COGs).  
COG Functional category Gene (n) 
C Energy production and conversion 16 
D Cell cycle control, cell division, chromosome partitioning 3 
E Amino acid transport and metabolism 12 
F Nucleotide transport and metabolism 1 
G Carbohydrate transport and metabolism 9 
H Coenzyme transport and metabolism 14 
I Lipid transport and metabolism 11 
J Translation, ribosomal structure and biogenesis 11 
K Transcription 4 
L Replication, recombination and repair 15 
M Cell wall/membrane/envelope biogenesis 13 
N Cell motility 2 
O 
Post translational modification, protein turnover, 
chaperones 
9 
P Inorganic ion transport and metabolism 14 
Q 
Secondary metabolite biosynthesis, transport and 
catabolism 
8 
R General function prediction only 9 
S Function unknown 12 
T Signal transduction mechanism 8 
V Defence mechanism 7 
 COG not designated 219 
 
Reproduced with permission from Gautam et al. Infect Dis (Lond). (2017). 
Copyright Informa UK Limited.
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3.2.4.3 Identification of Differential Gene content in the ‘Rangipo’ 
Strain  
To determine whether the Rangipo strain carries genes that are absent in 
the reference H37Rv strain, I investigated the unmapped reads (generated 
after assembly with H37Rv) that otherwise, in routine analyses would have 
gone unnoticed. This resulted in the detection of five genes in the Rangipo 
strain that were not present in the H37Rv genome. Upon analysing the 
presence of these genes in other M. tuberculosis strains using BLASTP 
analyses (Altschul et al., 1990), an orthologue of each gene was detected 
in M. tuberculosis CDC1551 strain. These include orthologues of 
transcriptional regulator protein EmbR2 (MT3428), molybdopterin cofactor 
biosynthesis protein A (MT3427), molybdopterin cofactor biosynthesis 
protein B (MT3426), an extended-length DNA helicase (MT2082), and an 
additional copy of adenylate cyclase (MT1360) in CDC1551 strain. 
Polymerase chain reaction rather than Southern Blotting was performed on 
the Rangipo isolates and H37Rv using primers for the genes (MT3426, 
MT3427, MT3428, MT2082 and MT1360) to confirm their presence and 
absence as indicated by the genome sequence analysis. No amplified 
products were observed in H37Rv in the agarose gel electrophoresis. 
However, bands were visible for all the five genes in the Rangipo strain 
which were confirmed by the Sanger sequencing of PCR amplified products. 
Presence of these five genes has previously been reported in the annotated 
genome of M. tuberculosis strain CDC1551 by Fleischmann et al 
(Fleischmann et al., 2002). Furthermore, the Rangipo associated five genes 
were examined in the annotated genomes of additional M. tuberculosis 
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lineage 4 strains i.e. Erdman and Haarlem. The Erdman strain possessed 
an orthologue gene for MT3427 while Haarlem strain contained orthologues 
of MT3428, MT3427 and MT2082 (Figure 3.1) (Gautam et al., 2017a). 
However, a preliminary investigation suggests the presence of sequence 
homology of Rv3109 (MoaA1) and Rv0869c (MoaA2) in the Rangipo strain 
with 100% similarity at the nucleotide level. 
 
 
Figure 3.1. Identification of additional genes in the Rangipo strain and 
annotated reference genomes of M. tuberculosis.  
A generalized time reversible (GTR) substitution model-based maximum-
likelihood phylogenetic tree was built including nine Rangipo strains and 
four lineage 4 reference strains: CDC1551 (SRX393042); Haarlem 
(SRX347319); Erdman (SRX364193); and H37Rv (NC_000962.3) using 
PhyML. M. canettii reference genome (HE572590.1) was used to root the 
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tree. Black squares represent the presence of a particular gene while clear 
squares indicate their absence.   
Reproduced with permission from Gautam et al. Infect Dis (Lond). (2017). 
Copyright Informa UK Limited. 
 
3.2.4.5 Consensus Genome Assembly 
A total of 2,128,439 paired-end reads of Rangipo isolate 494 were mapped 
to the H37Rv reference genome. This yielded an average read depth of 45-
fold, covering 99.5% of the reference genome. A total of 851 variant sites 
were identified relative to the H37Rv genome and consisted of 782 single-
nucleotide variants (SNVs) and 69 insertions/deletions. Five hundred and 
eighty-seven of the variants were nonsynonymous, of which 549 were SNVs 
and 38 were insertions/deletions. Drug resistance determining mutations 
were predicted using PhyResSe database (Feuerriegel et al., 2015) which 
identifies the mutations associated with first and second-line drug resistance 
in TB from whole-genome sequence data. For example, the database 
detects single nucleotide polymorphisms in katG, inhA, ahpC, rrs, rpsL, 
embA and embC in 100% agreement with other methods (Feuerriegel et al., 
2015). In terms of genotypic drug susceptibility testing, no mutation 
associated with drug resistance in M. tuberculosis was detected in Rangipo 
isolate 494 which is consistent with the phenotypic drug susceptibility profile 
as determined on MGIT cultures of the isolate by LabPLUS Ltd, Auckland.  
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For public access, the whole-genome shotgun project of M. tuberculosis 
Rangipo strain isolate number 494 has been deposited in 
DDBJ/EMBL/GenBank under the accession no. LXWG00000000.  
  
3.3 Discussion 
Multiple outbreaks of TB in New Zealand have been associated with the M. 
tuberculosis Rangipo strain (De Zoysa et al., 2001; McElnay et al., 2004). 
In this work, I performed whole-genome sequencing to investigate the 
genome of the Rangipo strain, in particular, variants in virulence-related 
genes. A total of nine isolates representing the Rangipo genotype were 
sequenced and analysed with respect to M. tuberculosis reference strains, 
H37Rv, CDC1551, Haarlem and Erdman. 
There were 700 single locus variants common to all nine isolates of Rangipo 
strains when mapped with the genome of the reference strain, H37Rv. The 
majority of these polymorphisms (n=592, 84.5%) were detected in the 
coding regions which consisted of 386 non-synonymous variants. Among 
these 386 NS-SLVs, 12 were detected in genes that were previously linked 
to mycobacterial virulence (Forellad et al., 2013). These include the genes 
aceAa, fadD28, kefB, mce1F, mycP1, pckA, pepD, phoR, pks15, plcB, 
pstA1 and pstS1. For example, decreased number of M. tuberculosis in the 
spleen and lungs of infected mice and their poor survival in macrophage 
cells derived from murine and human monocytes have been associated with 
a mutation in aceAa, isocitrate lyase gene (Munoz-Elias & McKinney, 2005). 
An essential role of the PhoPR system has been described for M. 
tuberculosis growth under low Mg2+ concentrations in vitro, and in 
 76 
 
macrophage and mouse infection models (Walters et al., 2006). A reduction 
in phenolic glycolipid production associated with a pks15/1 mutation has 
been related to decreased M. tuberculosis virulence in the meninges of 
rabbits (Tsenova et al., 2005). Similarly, triple plcABC or quadruple 
plcABCD mutations have been found to exhibit reduced growth of M. 
tuberculosis in the mouse infection model during their late phase of infection 
(Raynaud et al., 2002). It should be noted that the polymorphisms reported 
above are present in genes that have been previously related to the 
virulence of M. tuberculosis and may or may not alter the gene function. 
Therefore, validation of their specific role in the pathogenesis of M. 
tuberculosis requires further experimentation.  
In addition to non-synonymous SLVs, this study identified the differential 
carriage of genes in the Rangipo strain that were absent in H37Rv. The 
orthologues of additional Rangipo genes were identified in a clinical strain, 
CDC1551 associated with an outbreak of TB. Three of these genes have 
previously been related to mycobacterial virulence and include CDC1551 
orthologue MT3428 (transcriptional regulator protein EmbR2), MT3427 
(molybdopterin cofactor biosynthesis protein A), and MT3426 
(molybdopterin cofactor biosynthesis protein B). An orthologue of the 
H37Rv transcriptional regulator embR was reported in CDC1551 strain 
(Molle et al., 2008). The phosphorylation of embR by serine/threonine 
protein kinase (pknH) leads to the activation of the embCAB gene 
associated with the biosynthesis of a key M. tuberculosis cell wall 
constituent, arabinogalactan. In contrast to embR, embR2 is not 
phosphorylated by pknH (Molle et al., 2008) but inhibits the pknH autokinase 
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activity and embR phosphoryl transfer (Papavinasasundaram et al., 2005). 
In comparison to the parental strain of M. tuberculosis, a pknH mutant 
replicated and survived more resulting in the increased load of infecting 
bacilli in the lungs and spleen of the mouse (Papavinasasundaram et al., 
2005). Hence, the role of embR2 in mycobacterial physiology and 
pathogenesis has been predicted through its regulation of the pknH/embR 
pair (Molle et al., 2008). In addition to the Rangipo and CDC1551 strains, 
embR2 orthologues were detected in the lineage 4 Haarlem strain but not 
in the Erdman strain of M. tuberculosis (Figure 3.1). 
The orthologues of MT3427 and MT3426 in CDC1551 have been related to 
the production of molybdopterin cofactor (MoCo) biosynthesis proteins. 
MoCo functions as an essential cofactor for enzymes involved in redox 
reactions, for example, narGHI-encoded nitrate reductase that has been 
reported to be involved in M. tuberculosis adaptation in hypoxic conditions 
(Williams, Mizrahi, & Kana, 2014) and persistence in guinea pig lungs 
(Williams et al., 2015). The MT3427, MoCo biosynthesis protein A (MoaA) 
participates in the conversion of guanosine triphosphate to cyclic 
pyranopterin monophosphate (Williams, Kana, & Mizrahi, 2011). On the 
other hand, MT3426, MoCo biosynthesis protein B (MoaB) is involved in a 
key step of MoCo biosynthesis, the adenylation of molybdopterin (Williams, 
Mizrahi, & Kana, 2014). In addition to the above mentioned three genes, an 
extended-length DNA helicase (MT2082, 1606 amino acids), and an 
additional copy of adenylate cyclase (MT1360) were also identified in the 
Rangipo strain but not in the reference strain H37Rv. The functional role of 
 78 
 
the extended length DNA helicase and the extra copy of adenylate cyclase 
in the virulence of the Rangipo strain awaits further studies.   
An observation similar to the Rangipo and CDC1551 strain in terms of the 
presence of five additional genes was described in clinical isolates from 
Russia (Azhikina et al., 2006). In addition to these genes, the authors 
reported the detection of a truncated copy of plcD gene corresponding to 
the first 843 nucleotides of total 1,545 base pairs of the MT1799 gene in 
CDC1551. Notably, a truncated plcD gene was detected in the Rangipo 
strain which had first 905 nucleotides similar to CDC 1551 orthologue 
MT1799.  Furthermore, I analysed the publicly available whole-genome 
sequences of M. tuberculosis strains associated with outbreaks of TB in 
Germany (Roetzer et al., 2013), Guatemala (Saelens et al., 2015), Korea 
(Han et al., 2015), and the UK (Török et al., 2013) for their presence of five 
additional genes detected in the New Zealand outbreak Rangipo strain. All 
the genomes of the outbreak strains investigated were similar in terms of 
their possession of genes encoding moaA and moaB. It is possible that the 
presence of additional virulence related genes is associated with increased 
virulence of M. tuberculosis strains isolated during an outbreak. Translation 
of these genomic data requires verification in an in vivo infection model. 
The above findings highlight the limitations of M. tuberculosis reference 
genome H37Rv in the detection of virulence-related loci. In a recent 
publication (O'Toole & Gautam, 2017), we reviewed the literature regarding 
the properties of H37Rv that possibly limits its use as a sole reference strain 
in tuberculosis studies.  
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H37Rv in itself is not a clinical isolate but a laboratory derivative of H37 
which was grown from a patient’s specimen at the Trudeau Institute, 
Saranac Lake, New York in 1905 (Kubica, Kim, & Dunbar, 1972). The 
phenotypic similarity of H37Rv with Robert Koch’s description of TB causing 
bacteria (Koch, 1882) and its widespread global distribution and use led the 
emergence of H37Rv as a principal reference strain in diagnostics (Zhang 
et al., 2009) and studies on TB including vaccine design (Kaplan, 2005), 
therapeutics (Dutta et al., 2013), epidemiology and genomics (Mestre et al., 
2011; Roetzer et al., 2013; Walker et al., 2015). The highly monomorphic 
feature of M. tuberculosis and the availability of the genome of H37Rv in the 
highly curated form in databases used for gene annotations, transcriptomic 
and proteomic studies did not warrant the search for additional reference 
genomes of M. tuberculosis until now.  
However, there are reports suggesting the limitations in the robustness of 
using M. tuberculosis H37Rv as a sole reference strain in phenotypic and 
genotypic studies. The H37Rv strain has been associated with the failure to 
develop clinical TB when inoculated in low dose in the rhesus monkey 
(Gormus et al., 2004) and slower growth rate as compared to the isolates 
obtained from an infected patient (Zhang et al., 1998). De Groote and 
colleagues recommended the inclusion of an additional reference strain in 
in vivo drug efficacy studies (De Groote et al., 2012) while Marquina-Castillo 
et al concluded “the current use of H37Rv as the standard for animal models 
may be flawed because there were important differences in pathology 
caused by H37Rv” (Marquina-Castillo et al., 2009). The apparent difference 
in the virulence of the H37Rv strain may have occurred due to their multiple 
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passages in the laboratory over the longer period of time. Notable genetic 
differences related to the virulence of H37Rv strain include, +G insertion at 
-74 position upstream of the whiB6 (Rv3862c) start codon (Solans et al., 
2014), Leu152Pro substitution in PhoR (Rv0758) (Schreuder et al., 2015), 
moa gene containing RvD5 region (Brosch et al., 2002), and the absence 
of genes encoding nicotinamide adenine dinucleotide phosphate dependent 
oxidoreductase, and iron-regulated elongation factor (Periwal et al., 2015). 
Furthermore, H37Rv features the deletion of region RvD1 to RvD6 which 
are intact in CDC1551 (Zheng et al., 2008). It is noteworthy that CDC1151 
is a highly transmissible clinical isolate of TB outbreak reported in 
Tennessee and Kentucky in the mid-1990s (Valway et al., 1998). A plausible 
conclusion regarding the difference in the virulence of H37Rv and CDC1551 
may be related to their variation in gene content.  
With the aim of reducing limitations associated with gene absences in the 
H37Rv reference genome, Okumura and colleagues developed a virtual 
consensus genome of M. tuberculosis (Okumura et al., 2015). This virtual 
genome was created by merging sequences of 19 M. tuberculosis complex 
strains resulting in its total length of 4,991,559 base pairs making it larger 
than H37Rv (NC_000962.3) by 580,027 base pairs. The possibility of 
inclusion of a virtual reference genome in the analysis of a clinical isolate of 
M. tuberculosis depends on its ability to detect the full repertoire of genes in 
the latter.  
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3.4 Conclusions and Recommendations 
a) There are key differences between the New Zealand TB outbreak 
Rangipo strain and M. tuberculosis reference genome H37Rv in 
regard to virulence related genes. These were identified either as 
single locus variations or the presence of the additional genes in the 
Rangipo strain. Further studies (in vivo models) are required to 
elucidate the role of these variations to the infectivity of the Rangipo 
strain.  
b) The Rangipo related differential carriage of virulence related genes 
is not an exclusive feature of this strain but has been detected in 
clinical isolates including M. tuberculosis CDC1151 strain.  
c) A similarity between TB outbreak strains reported from different parts 
of the world was their presence of moaA and moaB genes that were 
absent in M. tuberculosis H37Rv.  
d) In a preliminary analysis of whole-genome sequence data, we 
detected genes (with functional annotation) present in H37Rv but not 
in the Rangipo genome. These include, Rv1758 (cutinase 1), Rv1760 
(diacylglycerol acetyltransferase), Rv2653c (toxin) and Rv2654c 
(antitoxin). Therefore, based on differential genome content in the 
outbreak strain and reference genome, we conclude that 
incorporation of H37Rv as a sole reference genome masks the 
detection of virulence related genes in M. tuberculosis. Based on this 
study, I recommend the inclusion of more than one reference 
genome while studying the virulence related gene in M. tuberculosis.  
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Chapter 4 
Molecular Epidemiology of Tuberculosis in Tasmania, 
Australia 
 
4.1 Introduction 
Tuberculosis is a nationally notifiable disease across all states and 
territories of Australia (Toms et al., 2017). Tasmania is an island state in the 
southern coast of Australia with a population of approximately 0.5 million 
people (Australian Bureau of Statistics, 2014). The historical evidence of TB 
in Tasmania dates back to 1804 when Colonel David Collins documented 
the evidence of “consumption” in one of the settlers in Hobart (Roe, 1999). 
Tuberculosis remained one of the major public health problems in Tasmania 
during the 1940s when the state’s TB incidence rate was almost double the 
national rate (103.8 versus 59.3 per 100,000 population) (Communicable 
Disease Intelligence, 2003). By 2014, Tasmania is at the lowest end of the 
TB burden among states and territories in Australia with the incidence rate 
of 1.7/100,000 person (Toms et al., 2017). Although the published records 
describing the epidemiology of TB in Tasmania are limited, the disease is 
believed to occur as discrete cases with the majority being imported from 
other jurisdictions. In addition, the declaration of the eradication of bovine 
TB from cattle in 1975 from Tasmania as part of the Brucellosis and 
Tuberculosis Eradication Campaign (BTEC) in Australia has been 
considered to eliminate the primary source of bovine TB in humans (More, 
Radunz, & Glanville, 2015).  
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In this study, I employed whole-genome sequencing to generate the 
genomic data of M. tuberculosis complex strains isolated in Tasmania and 
correlated it with the public health surveillance records to report the 
molecular epidemiology of TB in Tasmania.  
 
4.2 Methods 
 
4.2.1 Study Design  
Mycobacterium tuberculosis isolates reported in Tasmania were collected 
from the Royal Hobart Hospital located in Tasmania and Victorian Infectious 
Diseases Reference Laboratory, Victoria, Australia. A total of 18 cultured 
isolates representing 62.1% of total TB (n=29) notifications inclusive of three 
consecutive calendar years, 2014-2016, were studied. In addition to the 
clinical isolates of M. tuberculosis, patient data of respective cases were 
obtained. The samples were imported to the School of Medicine, University 
of Tasmania where whole-genome sequencing was performed and 
analysed using bioinformatic tools.  
Ethical approval to conduct the study was obtained from the Tasmanian 
Health and Medical Human Research Ethics Committee (H0016214). 
 
4.2.2 Culture and Drug Susceptibility Testing for M. tuberculosis 
Samples collected from suspected cases of tuberculosis were cultured 
using two solid media (Brown and Buckle agar and Löwenstein-Jensen 
agar) and a liquid culture system using Mycobacterial Growth Indicator 
Tubes (MGIT) following the standard protocol (Global Laboratory Initiative, 
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2014). The cultured isolates were stained using the Ziehl-Neelsen staining 
procedure and tested for TB MPT64 antigen (a Standard Diagnostics Bioline 
TB MPT64 antigen test). Drug susceptibility testing of M. tuberculosis 
isolates was performed using the MGIT system (Global Laboratory Initiative, 
2014).  
 
4.2.3 Extraction of M. tuberculosis DNA  
The genomic DNA was isolated from 1.5 mL liquid media cultures of M. 
tuberculosis. The suspension was heat treated at 80°C for 1 hour before 
centrifuging at 8000 rpm for 3 minutes at room temperature to obtain the 
cell pellet. The pelleted cells were resuspended in 200 μL phosphate-
buffered saline to which 25 µL of 10 mg/mL lysozyme were added. The 
lysozyme treated cells were initially incubated at 37°C for 1 hour followed 
by incubation at 95oC for 15 minutes. 30 μL proteinase K (10 mg/mL) was 
added to the mixture and then incubated for 30 minutes at 55°C. The 
extraction of mycobacterial DNA was then performed using a Qiagen 
DNeasy Blood and Tissue kit following the manufacturer’s instructions. The 
extracted DNA was treated with 1 µL of RNase A (7000 units/mL, Qiagen) 
and purified using the High Pure PCR Template Preparation Kit for 
downstream whole-genome sequencing as discussed in Chapter 2.  
 
4.2.4 Whole-genome Sequencing and Data Analysis  
Whole-genome sequencing of the M. tuberculosis isolates detected in 
Tasmania during 2014 to 2016 was performed on an Illumina MiSeq 
platform as described in Chapter 2.  
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The data analyses pipeline involves: a) prediction of mycobacterial lineage, 
b) detection of drug resistance determining mutations, c) building 
phylogenetic relationships between the isolates and d) determining single 
nucleotide polymorphism difference between the isolates to infer 
transmission network. Mycobacterial lineages were predicted with TB 
Profiler database (Coll et al., 2015). The drug resistance determining 
mutations were detected using the PhyResSE database (Feuerriegel et al., 
2015) followed by manual checking of the mapped sequences. A maximum 
likelihood phylogenetic inference tree rooted to Mycobacterium canettii was 
built in PhyML using the generalised time reversible (GTR) substitution 
model (Guindon, & Gascuel, 2003). Single nucleotide polymorphisms with 
respect to the reference genome H37Rv were detected as described in 
chapter 3, except we did not look for differential genome content and 
polymorphisms in genes associated with mycobacterial virulence in this 
chapter.  
  
4.2.5 Identification of Tuberculosis Transmission Network in Tasmania 
To establish evidence of recent TB transmission, single nucleotide 
polymorphic differences between the M. tuberculosis isolates were 
calculated. The isolates were associated in the same transmission network 
when they differed by ≤5 SNPs while >12 SNP differences excluded the 
isolates from the transmission network (Nikolayevskyy, Niemann & 
Drobniewski, 2016; Walker et al., 2013). These SNP cut-off values are likely 
affected by the difference in the time of sample collection, the incidence of 
TB in the local setting and homogeneity of M. tuberculosis strains in specific 
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geographical regions (Chad, 2014; Hatherell, 2016). Therefore, 
epidemiological information was analysed together with the genomic data 
to determine the relatedness between the cases. A possible cluster of TB 
was defined based on the National Tuberculosis Advisory Committee of 
Australia’s guidelines which states that “A ‘possible cluster’ will be any 2 or 
more active cases with the same genotype of M. tuberculosis where 
temporal and geospatial association is plausible, but no direct 
epidemiological link is identified” (Denholm et al., 2016). Mycobacterium 
tuberculosis isolates belonging to same global lineage were analysed for 
SNP difference and spatiotemporal linkage. In addition, the Total 
Genotyping Solution for TB (TGS-TB) database (Sekizuka et al., 2015) was 
used to generate the in silico spoligotype pattern of M. tuberculosis isolates. 
This was then compared with the publicly available data of M. tuberculosis 
spoligotype reported from the patient’s country of origin. 
 
4.3 Results  
 
4.3.1 Demographic Features of Patients Detected with TB in Tasmania  
The public health surveillance records of TB cases in Tasmania during 2014 
to 2016 were analysed for demographic and clinical information (Table 7) 
(Gautam et al., 2018). Out of a total 18 isolates of M. tuberculosis 
sequenced in this study, 7 were reported in 2016, 6 in 2015 and 5 during 
2014. The major proportion (83.3%, n=15 out of 18) of the TB isolates were 
collected from foreign-born individuals while people born in Australia 
constituted 16.7% (n=3) cases. The mean age of the studied cases was 
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33.6 years (range, 3 months to 70 years). Pulmonary form of TB was 
detected in 77.7% (n=14) individuals while extrapulmonary TB (EPTB) 
accounted for 22.2% cases (n=4). Specimens for four individual cases of 
EPTB were collected as paraspinal aspirate, bone tissue, urine, and colon 
tissue biopsy. 
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Table 7. Demographic and specimen information for tuberculosis cases (n = 18) in Tasmania from 2014 to 2016.  
Isolate Sex Age Specimen Year Lineage Origin 
RHH2 female 23y Sputum 2015 1 Philippines 
RHH3 male 62y Sputum 2015 3 Nepal 
RHH4 female 33y Sputum 2016 4 Thailand 
RHH5 male 24y Paraspinal aspirate 2015 1 Myanmar/Malaysia 
RHH6 male 20y Osteomyelitis  2014 3 Nepal 
RHH7 female 45y Sputum 2014 4 New Zealand 
RHH8 male 20y Sputum 2016 2 Malaysia 
RHH9 male 3m Gastric aspirate 2014 4 New Zealand 
RHH10 male 23y Sputum 2016 3 Nepal 
RHH11 female 49y Sputum 2015 3 Nepal 
RHH12 male 1y Gastric aspirate 2016 1 Philippines 
RHH13 male 26y Sputum 2015 3 Nepal 
RHH14 male 1y 8m Gastric aspirate 2015 3 Nepal 
RHH15 female 67y Sputum 2014 4 Australia 
TTB1* male 68y Urine 2016 M. bovis BCG Australia 
TASMDR1 male 36y Colon tissue 2016 2 Vietnam 
TTB3 male 36y Sputum 2016 1 Philippines 
TASMB14 male 70y Sputum 2014 M. bovis Australia 
*Obtained from the patient receiving BCG as a treatment for his bladder cancer  
Reproduced with permission from Gautam et al. PLoS ONE (2018). Copyright Gautam et al.
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4.3.2 Lineage Distribution of M. tuberculosis Complex in Tasmania  
The whole-genome sequence data of Tasmanian M. tuberculosis isolates 
(n=18) were genotyped using the PhyResSE and TB Profiler databases 
(Coll et al., 2015; Feuerriegel et al., 2015) for their distribution into different 
lineage types (Figure 4.1) (Gautam et al., 2018). The East-African Indian 
lineage 3 (n = 6, 33.3%) M. tuberculosis was predominant and was followed 
by the Euro-American lineage 4 (n = 4, 22.2%), Indo-Oceanic lineage 1 (n 
= 4, 22.2%) and East-Asian lineage 2 (n=2, 11.1%) isolates. There was 1 
case of human TB caused by M. bovis and a case of BCG-osis in 2016.  
 
Figure 4.1. Relative frequency of Mycobacterium tuberculosis complex (n 
=18) lineages in Tasmania from 2014 to 2016.  
Reproduced with permission from Gautam et al. PLoS ONE (2018). 
Copyright Gautam et al. 
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4.3.3 Identification of Clusters of TB in Tasmania  
A phylogenetic tree of the isolates of M. tuberculosis collected in Tasmania 
was constructed using PhymL (Guindon & Gascuel, 2003). The clade 
specific categorisation of isolates in a maximum likelihood phylogenetic tree 
was in agreement with the lineage classification obtained using the 
PhyResSE and TB Profiler databases (Figure 4.2) (Gautam et al., 2018). 
 
 
 
Figure 4.2. Phylogenetic relationship of M. tuberculosis complex isolates 
obtained in Tasmania from 2014 to 2016.  
Generalised Time Reversible substitution model generated using PhyML 
(bootstraps 100). TASMB14 and TTB1 constitute isolates of M. bovis and 
M. bovis BCG, respectively. The Gagneux lineage numbers are indicated to 
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the right of each isolate on the phylogenetic tree. The colour coded boxes 
represent isolates representing possible clusters of TB in Tasmania.  
Reproduced with permission from Gautam et al. PLoS ONE (2018). 
Copyright Gautam et al. 
 
The TB transmission network in Tasmania was inferred based on the single 
nucleotide polymorphic differences observed between isolates of the same 
lineage type and phylogenetic clade. Two clusters of TB were identified in 
Tasmania. The first cluster (cluster 1) consisted of four isolates (RHH3, 
RHH11, RHH13, and RHH14) of lineage 3 M. tuberculosis that were 
separated by zero SNPs. This is evident of the TB transmission within the 
same network involving four individuals of cluster 1 based on the cut-off of 
≤5 SNP differences between the isolates (Nikolayevskyy, Niemann, & 
Drobniewski, 2016; Walker et al., 2013). The patient record of four members 
of cluster 1 TB cases in Tasmania revealed their belonging to the same 
family originating from Nepal. These cases of drug susceptible pulmonary 
TB were detected in the gastric aspirate sample from a child and from 
sputum specimens collected from three adults between May and August 
2015. In silico spoligotype data were obtained for cluster 1 isolates after 
importing raw sequence Fastq files into the TB profiler database (Coll et al., 
2015). All four lineage 3 cluster isolates matched the CAS1_Delhi 
spoligotype of the Spoligotype International Type 26 (Figure 4.3) (Gautam 
et al., 2018). A literature search was performed to identify the reports on M. 
tuberculosis genotypes from Nepal. Malla and colleagues analysed 261 M. 
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tuberculosis isolates obtained from the cases of pulmonary TB between 
August 2009 to August 2010 in Nepal using spoligotyping. Lineage 3 M. 
tuberculosis were predominantly (40.6%) reported in the study with 
approximately 50% of these isolates belonging to CAS1_Delhi spoligotype 
(Malla et al., 2012).  
 
Figure 4.3. Distribution of in silico generated spoligotypes across the 
culture-positive Tasmanian TB isolates analysed from 2014-2016.  
aThe in silico derived spoligotype of the four Tasmanian Lineage 3 cluster 
isolates (RHH3, RHH11, RHH13, RHH14) and a fifth lineage 3 isolate 
(RHH10) matched Spoligotype International Type 26 of the CAS1_Delhi 
spoligotyping family which accounted for approximately 50% of lineage 3 M. 
tuberculosis isolates in Nepal in a previous analysis (Malla B, 2012). bThe 
in silico derived spoligotype of the M. bovis isolate (TASMB14) matches that 
of human M. bovis cases that were reported in other Australian 
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states/territories between 1977 and 1989 (Cousins, Williams, & Dawson, 
1999). 
Reproduced with permission from Gautam et al. PLoS ONE (2018). 
Copyright Gautam et al. 
 
In addition, the second cluster of TB (cluster 2) was detected in this study. 
Two isolates (RHH7 and RHH9) of lineage 4 M. tuberculosis obtained from 
cases of drug susceptible pulmonary TB during November to December 
2014 exhibited zero SNP difference between one another. This 
transmission involved a mother and her newly born child coming from New 
Zealand. Although lineage 4 M. tuberculosis is common (70.5%, n=67/95) 
in New Zealand born population (Yen et al., 2013), genomic similarities were 
not observed between the isolates representing lineage 4 Rangipo 
genotype discussed in chapter 3 and members of TB cluster 2 in Tasmania.  
Apart from 6 isolates of M. tuberculosis representing two TB clusters in 
Tasmania, all other isolates (n=12) were phylogenetically unrelated in terms 
of their SNP differences. Among these unique cases, two isolates (TTB3 
and RHH12) obtained from Philippines country-of-origin individuals were 
closely related in terms of their SNP difference (n=74). Both the isolates 
belonged to lineage 1 M. tuberculosis which is the most common type 
reported in the Philippines (Gagneux, 2006; Reed, 2009). However, no 
epidemiological connections between these cases were apparent to 
categorise them as a “probable cluster” and the number of SNP differences 
was well above the standard 5 SNP threshold.  
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4.3.4 A Human Case of Bovine TB in Tasmania 
An isolate (TASMB14) obtained from the TB cases detected in 2014 in 
Tasmania was identified as M. bovis. This human case of bovine TB was 
detected in a sputum specimen obtained from an Australia born individual 
aged ≥60 years with comorbidity of chronic obstructive pulmonary disease. 
The isolate was susceptible to first-line anti-tuberculosis drugs isoniazid and 
rifampicin. Whole-genome sequencing revealed the presence of 
pyrazinamide resistance conferring polymorphism in the Rv2043c gene 
(pncA, Cac/Gac, H57D) and RD1 region (Rv3871 to Rv3879c) which are 
genomic features of M. bovis. Furthermore, the in silico spoligotype of 
TASMB14 matched that of earlier reported human TB cases due to M. bovis 
in Australia in 1977 and 1989 (Cousins, Williams, & Dawson, 1999) (Figure 
4.3) (Gautam et al., 2018). 
The genome sequence of M. bovis BCG isolated from the urine sample of 
a patient receiving BCG for the treatment of bladder cancer was mapped 
against M. bovis NC_008769 (BCG Pasteur1173P2). The isolate TTB1 had 
99.58% template coverage with NC_008769 at the read depth of 16.97. 
Hence, we assumed that the BCG strain isolated from this particular patient 
was the same given for his treatment and did not analyse and interpret the 
genomic feature of TTB1 isolate further. 
 
4.4 Discussion 
In this study, I reported the first detailed analysis of the epidemiology of 
tuberculosis in Tasmania combining microbial whole-genome sequence 
and public health surveillance records. A total of 18 cultured isolates of M. 
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tuberculosis complex collected in Tasmania from 2014 to 2016, were 
examined. The major proportion of TB cases (83%, n=15/18) examined in 
this study were associated with overseas born individuals. This is 
comparable to the national figure of Australia where 86% of TB cases in 
2014 (n=1151) were detected in foreign born patients (Toms et al., 2017). 
People with a history of travel or residence in high TB burden countries were 
the most common risk factor for TB in Australia (Toms et al., 2017).  
The lineage distribution of M. tuberculosis complex isolates in Tasmania 
was reported. Four out of seven global lineages of M. tuberculosis were 
detected in Tasmania and included globally distributed Euro-American 
lineage 4 and East-Asian lineage 2 and relatively restricted strains 
belonging to Indo-oceanic lineage 1 and East-African Indian lineage 3. M. 
tuberculosis East-African Indian Lineage 3 was predominant (33.3%) in 
Tasmania. All of the lineage 3 cases were detected in patients originating 
from South-Asia where this particular lineage type is more common. A 
strong association between lineage of M. tuberculosis prevalent in patient’s 
region of origin and isolates obtained from the migrant population in their 
current country of residence is well documented (Gagneux et al., 2006; Yen 
et al., 2013). There was no evidence supporting the spread of TB from the 
migrant population to the members of other communities in Tasmania. A 
number of studies conducted in Europe have identified that migrants are not 
likely to transmit TB to the local population (Barniol et al., 2009; Kamper-
Jorgensen, 2012). Furthermore, a systematic review designed to study the 
TB transmission dynamics between the foreign-born and native-born 
population in European Union/ European Economic Area concluded that 
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“TB in a foreign-born population does not have a significant influence on TB 
in the native population in EU/EEA” (Sandgren et al., 2014).  
Based on the whole-genome sequence data and patient variables, two 
possible clusters of M. tuberculosis were identified in Tasmania. The cases 
representing the largest cluster of TB in Tasmania (cluster 1) were detected 
within 3 months while cluster 2 cases were detected within 39 days. The in 
silico spoligotype of cluster 1 M. tuberculosis isolates matched the 
predominant spoligotype reported among the lineage 3 isolates in the 
patients’ country of origin, Nepal (Malla et al., 2012). The unavailability of 
whole-genome sequence data representing lineage 3 M. tuberculosis 
originating from Nepal limited the further analyses of transmission of cluster 
1 isolates detected in Tasmania. However, based on the epidemiological 
and genotypic data, the origin of cluster 1 M. tuberculosis isolates in 
Tasmania could possibly be assigned to the Nepal region. In a recent 
publication (Gautam et al., 2018) my co-authors and I concluded that “a 
number of the overseas-born patients who presented with TB in Tasmania 
probably acquired M. tuberculosis infection prior to their arrival in the state 
or in Australia”.  
Tuberculosis in migrants is more frequently detected than the native-born 
population in the low TB burden countries (Hanway et al.,  2016), including 
Australia (Toms et al., 2017). The Australian Government has endorsed the 
World Health Organization’s post - 2015 global TB strategy directed towards 
ending the global epidemic of TB by reducing the current TB incidence rate 
by 90% and TB mortalities by 95% by 2035 (Toms et al., 2017). Tasmania 
should achieve a 60% drop in current TB incidence rate by 2035 to achieve 
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this international target. Australian TB elimination program is well supported 
by the availability of health care programs, robust surveillance strategies 
and governance frameworks (Toms et al., 2017). However, challenges 
persist in terms of reducing the incidence of TB in overseas born individuals. 
The current Australian immigration policy requires applicants aged > 11 
years to undergo mandatory screening for TB if his/her intention is to stay 
is more than 6 months (Australian Government Department of Home Affairs, 
2018). This includes a test for active TB using a chest X-ray and other 
diagnostic tests when indicated. An individual testing positive for active TB 
is barred to enter Australia until completion of treatment and declaration of 
being free of active TB disease (Australian Government Department of 
Home Affairs, 2018). It should be noted that the TB screening tests for visa 
purposes for Australia are not intended to detect a latent form of TB. 
Arguably, reactivation of latent TB is a common feature of TB among foreign 
born individuals in low burden high income countries (Rickset al., 2011; 
White, & Houben, 2014). The incidence rate of TB in Australia is predicted 
to decrease when the number of TB cases in the Western Pacific and South-
East Asian regions decline (Toms et al., 2017). It is, therefore, the TB control 
policy of low burden countries (for example, Australia) should extend 
beyond their territories and support the high burden countries to contain the 
regional and global spread of TB.  
In addition to cases of human infection due to M. tuberculosis, a case of TB 
was reported due to M. bovis in Tasmania in 2014. This human case of 
bovine TB was detected in a sputum specimen obtained from an Australia 
born individual aged ≥60 years with a comorbidity of chronic obstructive 
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pulmonary disease. The isolate was susceptible to first-line anti-
tuberculosis drugs isoniazid and rifampicin. The case of M. bovis infection 
was detected in an Australia born male individual approximately 40 years 
after the last confirmed case of bovine TB in Tasmanian in 1975 (More, 
Radunz, & Glanville, 2015). The in-silico genotype of M. bovis detected in 
Tasmania matched with the earlier reports indicating human infection due 
to M. bovis in other Australian states and territories between 1977 and 1989 
(Cousins, Williams, & Dawson, 1999). No more epidemiological data were 
available to trace the source of pulmonary TB due to M. bovis in Tasmania. 
However, this case of M. bovis infection may possibly represent a 
reactivating case of latent TB that was acquired prior to the elimination of 
M. bovis from cattle in Tasmania. It should be noted that infection due to M. 
bovis may progress to active disease long after the exposure as explained 
by Cousins et al “because of the usual long incubation periods that can 
occur between infection and development of disease, and because of the 
possibility of disease reactivation, especially in elderly or 
immunocompromised patients, human tuberculosis caused by M. bovis is 
likely to continue to be diagnosed for many years to come” (Cousins, & 
Dawson, 1999). Although the human case of TB due to M. bovis is rare in 
Australia, vigilance should be maintained to control the re-emergence of this 
old zoonotic disease in Tasmania. Furthermore, TB due to M. bovis should 
be routinely distinguished with M. tuberculosis as the former is intrinsically 
resistant to one of the first line anti- tuberculosis drugs, pyrazinamide 
(Barouni et al., 2004). 
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4.5 Conclusions and Recommendations 
a) The majority of TB cases in Tasmania is detected in overseas born 
individuals.  
b) Although low in incidence rate, an epidemiological feature of TB in 
Tasmania resembles other jurisdictions in terms of the presence of 
clustered cases. 
c) The TB control strategy in Tasmania should be more focused on 
detecting cases in individuals originating from high TB burden 
countries.  
d) The detection of a human case of bovine TB in Tasmania cautions 
towards maintaining vigilance to control re-emergence of bovine TB 
in cattle and human. 
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Chapter 5 
Tracing the Source of the First- Case of Multi-Drug 
Resistant Tuberculosis in Tasmania 
 
5.1 Drug Resistant Tuberculosis  
Multi-drug resistant (MDR) tuberculosis refers to TB caused by an isolate of 
M. tuberculosis that is resistant to at least the two first line anti-TB drugs, 
isoniazid and rifampicin (World Health Organization, 2018i). The World 
Health Organization recommends MDR-TB treatment regime for rifampicin 
mono-resistant (RR) isolates (World Health Organization, 2016a) as RR is 
considered as a marker of MDR-TB in more than 90% cases (Drobniewski 
& Pozniak, 1996). An estimated 558,000 cases globally were resistant to 
rifampicin (RR-TB) in 2017 (World Health Organization, 2018d). Eighty-two 
percent (n=457,560) of these RR-TB cases were identified as MDR-TB. 
India (24%), China (13%) and the Russian Federation (10%) collectively 
shared approximately half (47%) of global MDR-TB cases in 2017 (World 
Health Organization, 2018d). Of the total MDR-TB cases, 8.5% (95% CI, 
6.2-11%) were extensively drug resistant TB (World Health Organization, 
2018d). In terms of treatment, drug susceptible TB cases were more 
successfully cured as compared to MDR and XDR form of TB in 2016 (82% 
versus 54% and 30% respectively) (World Health Organization, 2018d).  
In Australia, an estimated 25 (14-36) cases of MDR/RR-TB were notified 
among pulmonary TB cases in 2017 (World Health Organization, 2018). A 
total of 23 cases were bacteriologically confirmed for MDR/RR-TB, of which, 
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23 patients were enrolled for treatment (World Health Organization, 2018). 
In terms of treatment success, 78% of the new and relapse case, 75% of 
MDR/RR-TB and 100% XDR-TB was successfully achieved in their size of 
1371, 32 and 2 cohorts respectively (World Health Organization, 2018). In 
terms of patients’ country of origin, approximately 88% (n=15 out of total 17 
cases) of MDR/XDR-TB patients in 2014 in Australia were foreign born 
individuals (Toms et al., 2017). 
Tasmania exhibited the lowest TB incidence rate (1.7 per 100,000 
population) among 8 Australian states or territories in 2014 (Toms et al., 
2017). Here, I utilized whole-genome sequencing to define the genomic 
features and track the transmission of the first case of MDR-TB sequenced 
during the analysis of Tasmanian M. tuberculosis isolates as described in 
chapter 4 (section 4.2.4). 
 
5.2 Methods 
 
5.2.1 Whole-genome Sequencing of the First Isolate of MDR-TB in 
Tasmania  
One of the Tasmanian-collected TB isolates from 2014-2016 exhibited 
phenotypic drug resistance to isoniazid, rifampicin, ethambutol and 
pyrazinamide as determined by Victoria Infectious Diseases Reference 
Laboratory, Melbourne Australia (VIDRL). Whole-genome sequencing of 
this isolate was performed on an Illumina MiSeq platform as described in 
Chapter 2. 
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The raw sequence data were analysed for lineage type using the TB profiler 
database (Coll et al., 2015) and mutations associated with drug resistance 
were detected in PhyResSE database (Feuerriegel et al., 2015). This was 
followed by manual checking of the sequence for variants associated with 
drug resistance in M. tuberculosis. In addition, the Fastq files were imported 
onto the Geneious software suite (R 9.5) (Kearse et al., 2012) and analysed 
as described in Chapter 3. 
Ethical approval to conduct the study was obtained from the Tasmanian 
Health and Medical Human Research Ethics Committee (H0016214). 
 
5.2.2 Consensus Genome Assembly of First MDR-TB Isolate in 
Tasmania 
The paired end raw Fastq reads of the MDR-TB isolate reported for the first 
time in Tasmania were generated using an Illumina MiSeq sequencer. The 
Burrows-Wheeler Aligner (Li & Durbin, 2010) was used to map the Fastq 
files with the M. tuberculosis reference genome H37Rv (NC_000962). After 
mapping, the contigs were de novo assembled using the SPAdes assembler 
(version 3.7) (Bankevich et al., 2012) and ordered according to M. 
tuberculosis H37Rv using ABACAS (Assefa et al., 2009) for their deposition 
in public databases. The number of variants in the MDR-TB strain with 
respect to the H37Rv reference genome were determined using the SAM-
tools analyses suite. These variants were then annotated using the SnpEff 
analyses platform (Cingolani et al., 2012). To identify the presence of drug 
resistance determining mutations, paired end raw Fastq files were imported 
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onto publicly available PhyResSE database (Feuerriegel et al., 2015). The 
whole-genome shotgun project of the first MDR-TB isolate detected in 
Tasmania was submitted for deposition at DNA Data Bank of Japan, 
European Molecular Biology Laboratory and National Institute of Health 
genetic sequence database, GenBank and is available under accession 
number NTFG00000000. 
 
5.2.3 Tracing the Source of the First MDR-TB Case in Tasmania 
 The clinical and epidemiological information of the first case of MDR-TB 
detected in Tasmania were obtained from the treating physician at 
Launceston General Hospital, Tasmania. To establish a transmission 
network, a cut off of 5 or less single nucleotide polymorphisms between the 
isolates was used as described previously (Gautam et al., 2018; Walker et 
al., 2013). The difference in time of sample collection from different sources, 
TB incidence rate in the local setting and homogeneity of a particular M. 
tuberculosis strain in a specific geographical location may influence the SNP 
distance calculation to determine the transmission chain (Hatherell et al., 
2016; Migliori et al., 2008). To minimize potential bias that may occur when 
genomic data are solely used to infer recent transmission (Hatherell et al., 
2016 and Walker et al., 2013), we analysed the whole-genome sequence 
data together with epidemiological information to confirm recent 
transmission of MDR-TB in Tasmania.  
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5.3 Results 
 
5.3.1 Case of Drug Resistant TB in Tasmania 
Tasmania had been free of the multi-drug resistant form of TB until the first 
case of MDR-TB was diagnosed in 2016 in a Vietnamese-born individual at 
Launceston General Hospital. The patient was a 37-year-old male student 
who tested positive for latent TB in an interferon gamma release assay in 
February 2016 but exhibited no symptoms of pulmonary TB and reported 
negative in chest X-ray investigation and sputum smear microscopy and 
culture. A few months later, the patient presented with a complaint of 
abdominal pain consistent with colitis. A colon tissue biopsy sample was 
obtained and examined for microbiological features of M. tuberculosis 
infection. The sample was negative for smear microscopy but the growth of 
tubercle bacilli in culture evidenced the diagnosis of extra-pulmonary TB. 
Drug susceptibility profiling of the isolate was performed at VIDRL using 
Mycobacteria Growth Indicator Tube (MGIT) system. The isolate was 
recorded as resistant to isoniazid, rifampicin, ethambutol and pyrazinamide 
and susceptible to ethionamide, amikacin, capreomycin, kanamycin, 
ofloxacin and moxifloxacin by VIDRL. This confirmed the first reported case 
of multi-drug resistant isolate of M. tuberculosis in Tasmania (TASMDR1). 
 
 5.3.2 Genomic Features of TASMDR1   
The report on the genomic feature of TASMDR1 was published (Gautam, 
Mac Aogáin, & O’Toole, 2017) in Genome Announcements™, a publication 
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of American Society for Microbiology. This particular analysis was done to 
generate data on TASMDR1 and deposit it in the public databases. In the 
publication (Gautam, Mac Aogáin, & O’Toole, 2017), we mentioned “A total 
of 2,860,297 paired-end reads were mapped to the publicly available 
annotated genome of M. tuberculosis reference strain H37Rv (GenBank 
accession number NC_000962.3) (Cole et al., 1998) by Burrows-Wheeler 
alignment (Li & Durbin, 2010). This yielded an average read depth of 65.5-
fold, covering 97.8% of the H37Rv genome. A 4,230,496-bp draft genome 
assembly of 220 contigs was assembled de novo using the SPAdes 
assembler (v3.7) (Bankevich et al., 2012). A total of 1,553 variant sites were 
identified relative to the H37Rv genome and consisted of 1,408 single-
nucleotide variants (SNVs) and 145 insertions/deletions (indels size range, 
1 to 501 base pairs). Of the variants, 881 were nonsynonymous; of these, 
784 were SNVs and 97 were insertions/deletions. The genome of 
TASMDR1 displayed high-confidence single-nucleotide polymorphisms in 
genes correlating with antimicrobial drug resistance when analysed using 
the PhyResSE database (Feuerriegel et al., 2015). These included high-
confidence mutations in the katG gene (aGc/aCc, S315T) and rpoB gene 
(gAc/gGc, D435G; tCg/tTg, S450L), which underlie M. tuberculosis 
resistance to isoniazid and rifampicin, respectively (Eldholm et al., 2015; 
Rodwell et al., 2014). These data establish the genetic bases of the MDR 
phenotype exhibited by strain TASMDR1. Additional mutations were 
detected in the embB gene (Atg/Gtg, M306V) and pncA gene (cCg/cTg, 
P62L) that are associated with resistance to ethambutol and pyrazinamide, 
respectively (Cuevas-Córdoba et al., 2015; Miotto et al., 2014; Simons et 
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al., 2014; Starks et al., 2009)”. In addition to the drug resistance determining 
mutations reported by a clinical laboratory, this study identified genomic 
evidence of resistance of TASMDR1 towards streptomycin (rrs 
(MTB000019)) (Table 8) (Gautam et al., 2018). The PhyResSE and TB 
Profiler databases (Coll et al., 2015; Feuerriegel et al., 2015) predicted 
TASMDR1 as an isolate of M. tuberculosis belonging to the Beijing sub-
lineage of M. tuberculosis East Asian Lineage 2.  
This whole-genome shotgun project is available at DDBJ/ENA/GenBank 
under the accession number NTFG00000000. The version that has been 
described in the publication is NTFG01000000 (Gautam, Mac Aogáin, & 
O’Toole, 2017).  
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Table 8. Drug resistance determining mutations present in TASMDR1.  
Isolates Drug Gene Locus tag Mutation Genome location Substitution 
 
 
 TASMDR1 
Rifampicin rpoB Rv0667 gAc/gGc, tCg/tTg 761110, 761155 D435G, S450L 
Isoniazid katG Rv1908c aGc/aCc 2155168 S315T 
Pyrazinamide pncA Rv2043c cCg/cTg 2289057 P62L 
Ethambutol embB Rv3795 Atg/Gtg 4247429 M306V 
Streptomycin rrs MTB000019 a/c 1472359 a514c 
 
Reproduced with permission from Gautam et al. PLoS ONE (2018). Copyright Gautam et al. 
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5.3.3 Tracing the Source of TASMDR1 
The treating physician at Launceston General Hospital became aware that 
the Tasmanian MDR-TB patient was in close contact with his family member 
detected with multi-drug resistant pulmonary TB in Vietnam in 2012 prior to 
this arrival in Australia. I travelled to Cho Ray Hospital, Ho Chi Minh city, 
Vietnam to study the contact case in detail. The culture-based laboratory 
diagnosis (MGIT system) of an isolate obtained from the contact case was 
recorded as resistant to isoniazid, rifampicin, ethambutol, pyrazinamide, 
and streptomycin. In addition, genomic DNA of the M. tuberculosis isolate 
obtained from the contact case was shipped to the University of Tasmania 
for further analyses. This isolate obtained from Vietnam was labelled as 
VTB1. 
Whole-genome sequencing was performed on genomic DNA of VTB1 and 
data were analysed as described in chapter 2. The genomic data was 
interpreted together with the available epidemiological and clinical 
information (Table 9). The drug resistance profile and lineage typing of 
VTB1 were identical to TASMDR1, i.e. VTB1 belonged to East Asian L2 
(Beijing) and conferred exactly the same drug resistance determining 
mutations as of TASMDR1 i.e. isoniazid, rifampicin, pyrazinamide, 
ethambutol and streptomycin. In addition, no drug resistance determining 
mutations were detected for ethionamide, amikacin, capreomycin, 
kanamycin, ofloxacin and moxifloxacin. To build a transmission network, 
single nucleotide polymorphic differences between TASMDR1 and VTB1 
were calculated. The isolates were detected to separate from each other by 
zero SNP differences which is strongly indicative of their belonging to the 
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same transmission network. With an established epidemiological link of 
household contact and diagnosis of VTB1 case as an infectious form (i.e. 
pulmonary TB) of TB prior to TASMDR1, my co-authors and I in our recent 
publication (Gautam et al., 2019) paper concluded that “the Tasmanian 
patient contracted MDR-TB strain from his household contact early before 
his arrival to Tasmania which then reactivated from the latency and clinically 
presented as a case of multi-drug resistant extra-pulmonary TB in 2016 in 
Tasmania”.  
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 Table 9. Epidemiological and Clinical Profile of the First Case of MDR-TB Detected in Tasmania (TASMDR1) and its Contact 
(VTB1). 
Demographic and clinical details TASMDR1 VTB1 
Sex Male Female 
Age* 37 31 
Date of Detection 2016 2012 
Country of Origin Vietnam Vietnam 
Location of Diagnosis Launceston, Tasmania, Australia Ho Chi Minh City, Vietnam 
Epidemiological link                                       Household family members 
Clinical case  Extra-pulmonary TB Pulmonary TB 
Isolate M. tuberculosis M. tuberculosis 
Lineage East Asian L2 (Beijing) East Asian L2 (Beijing) 
Drugs Resistant Isoniazid, rifampicin, pyrazinamide, 
ethambutol and streptomycin 
Isoniazid, rifampicin, pyrazinamide, 
ethambutol and streptomycin 
Number of SNP Difference                                  Zero with respect to each other 
*Based on the year of diagnosis 
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5.4 Discussion 
In this study, I analysed the whole-genome sequence data and patient 
information to genetically and epidemiologically link the first case of MDR-
TB in Tasmania to its household contact in Vietnam. Australia is a low TB 
burden country with MDR-TB occurring in less than 2% of incident cases 
(Toms et al., 2017). The majority of MDR/XDR-TB cases in Australia are 
diagnosed among foreign born individuals, for example, 15 out of 17 cases 
of MDR-TB were reported in overseas born population in 2014 (Toms et al., 
2017). Francis and colleagues retrospectively reviewed the laboratory 
confirmed cases of MDR-TB in Australia reported during 1998-2012 and 
found that the majority of cases occurred in overseas-born individuals as 
compared to people born in Australia (94.7% versus 5.3% respectively, 
n=244) (Francis et al., 2018).  
In this study, I reported the genomic feature of the first case of MDR-TB 
detected in Tasmania (TASMDR1) in 2016. The source tracing of 
TASMDR1 was done using the epidemiological and whole-genome 
sequence data. Lalor and colleagues recently recommended the combined 
use of WGS and epidemiological information to investigate the clusters of 
MDR-TB (Lalor et al., 2018). The TASMDR1 patient originated from 
Vietnam and the source of this case was traced to his household contact in 
Vietnam. Vietnam ranked second (n=140) to India (n=223) in terms of TB 
patient’s country of origin in Australia (Toms et al., 2017). Vietnam is one of 
the high TB and TB/HIV burden countries (World Health Organization, 
2018h) where 4.1% of new and 17% of previously treated cases were 
detected as MDR/RR-TB. It is unlikely that the MDR-TB isolate in our study 
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was imported in the form of an active MDR-TB case from Vietnam to 
Tasmania. This is because the student detected with TASMDR1 would have 
undergone the mandatory pre-arrival health check-up including screening 
for active pulmonary TB during the process of his visa application to 
Australia. Furthermore, the patient did not exhibit clinical signs or symptoms 
of active pulmonary TB in early 2016 post arrival in Tasmania.  
Chest X-ray (CXR) imaging is a primary tool to screen for active TB in 
people entering Australia. The CXR is unreliable in detecting M. tuberculosis 
infection in extrapulmonary sites away from the lung periphery. Pollett and 
colleagues reported a median time of 5 years (0-41 years) to detect cases 
of extrapulmonary TB in people migrating from high burden countries to 
Australia and concluded that “Vigilance for extrapulmonary TB needs to 
remain high in those moving from high prevalence countries to Australia, 
even decades after immigration”. The authors further highlighted the 
challenge in the diagnosis of extra pulmonary TB in their well-equipped 
setting of Centre for Infectious Diseases and Microbiology, Western Sydney 
Local Health District where half of the extra-pulmonary TB did not produce 
microbiological evidence of the disease (Pollett et al., 2016). Globally, 14% 
of all TB cases are detected in extrapulmonary sites (World Health 
Organization, 2018d) and the complexity in the clinical and laboratory 
diagnosis of these cases pose a challenge for TB control programs, in 
particular, their spread from high to low TB burden settings in latent form. 
Clinically, the majority of TB cases among the foreign-born population in 
industrialised countries represent reactivation of LTBI rather than the 
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continuation of an existing case of active TB (Ricks et al., 2011; White & 
Houben, 2014). Therefore, detection of both the active and/or latent TB 
infection and their early management is the major focus in controlling TB in 
migrants and its spread. In addition to the diagnostic limitation, inability to 
clinically identify if M. tuberculosis associated with latent TB is susceptible 
or resistant to drugs adds uncertainties in selecting the effective treatment 
regime (Norbis et al., 2014). Poor compliance towards TB treatment in 
refugees and immigrants has been related to their issues of privacy, 
distress, shame and possible isolation (Wieland et al., 2012) and perceived 
side effects of medication (Wieland et al., 2012). A systematic review of a 
national estimate of MDR-TB risk factors in 6 European nations associated 
overseas birth as a risk of MDR-TB acquisition (odds ratio (OR) 2.46; 
95%CI, 1.86-3.24). As explained in chapter 4 “It is, therefore, the TB control 
policy of low burden countries should extend beyond their territories and 
support the high burden countries to contain the regional and global spread 
of TB”.  
 
5.5 Conclusion and Recommendations 
In a recent publication highlighting the intercontinental transmission of 
MDR-TB in Australia (Gautam et al., 2019), my co-authors and I concluded 
that “despite the immense prevalence of LTBI, there are few reports in the 
literature describing the translocation of the multi-drug resistant form of 
tuberculosis from one jurisdiction to another as a latent infection, and its 
subsequent emergence as active MDR-TB in a new host country. This type 
of international movement of TB is difficult to detect with existing pre-
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immigration TB screening practices that are reliant upon a chest x-ray-
based diagnosis of a current or previous episode of pulmonary TB. The 
silent international movement of MDR-TB in latent form, as is suspected in 
this case, is an area of concern”. Hence, caution needs to be maintained 
through tracing the source of MDR-TB cases and implementing TB control 
strategies to facilitate the early detection of drug resistance TB and limit their 
spread particularly in low prevalence setting like Tasmania.  
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Chapter 6 
Summary 
 
Tuberculosis remains a global public health emergency. The management 
of TB is largely impeded due to the limited protective efficacy of the BCG 
vaccine, diagnostic delay, and treatment failure either due to patient non-
compliance or poor allocation of resources. However, on a positive note, the 
global incidence of TB is decreasing by 2% per year and the introduction of 
new technologies have aided in the diagnosis and epidemiological typing of 
disease. My thesis is based on the application of whole-genome sequencing 
in functional and epidemiological typing of tuberculosis. Initially, I described 
an in-house protocol, adapted at Trinity College Dublin, to obtain whole-
genome sequence data of M. tuberculosis. Here, we modified the 
manufacturer’s protocol in terms of consumables and library normalization 
step.  A major advantage of doing so was the reduction in cost associated 
with consumables while obtaining quality data for downstream analyses. 
However, we did not validate the proposed method against any published 
protocol which is one of the limitations of the study. For the first section of 
my thesis, I hypothesised that virulence related genes of M. tuberculosis 
complex isolate capable of causing outbreaks vary at a certain level with 
respect to the reference strain H37Rv. To test my hypothesis, I performed 
functional genomic analyses of the New Zealand TB outbreak “Rangipo” 
strain. In this study, I reported differential carriage of virulence related genes 
and amino-acid changing mutations in genes previously related to 
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mycobacterial virulence. This further led to conclude that mapping whole-
genome sequence data with a widely adopted reference strain H37RV alone 
masks the detection of virulence related genes. Therefore, I recommended 
the inclusion of additional reference strains (for example CDC1551) while 
analysing the whole-genome sequence data of M. tuberculosis. 
In the second part, I performed molecular epidemiological typing of M. 
tuberculosis isolated in Tasmania during three consecutive calendar years 
(2014-2016). Here, I described for the first time a comprehensive report 
detailing the molecular epidemiology of TB in Tasmania. I reported the 
predominance of TB among non-Australia born individuals, lineage 3 as a 
dominant type and the detection of two clusters of TB cases in Tasmania. 
Furthermore, a human case of infection due to M. bovis was described in 
the study. For the third aim, I implemented WGS to trace the source of the 
first case of MDR-TB reported in Tasmania. The origin of TASMDR1 was 
located to Vietnam and evidence for its transmission to Tasmania in the 
latent stage was discussed. While addressing aim 2 and aim 3, I concluded 
that the epidemiological feature of TB in low burden setting of Tasmania is 
no different than other jurisdictions. Hence, vigilance should be maintained 
to timely detect the cases, in particular, migrant population coming from high 
burden countries.  
To summarize, this thesis demonstrated the application of whole-genome 
sequencing to study the functional genomics and epidemiology of M. 
tuberculosis.  
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Supplement 1 
Step by step guide to analyse the Fastq files using Geneious 
1. Download Geneious from https://www.geneious.com/  
2. Go to File | Import | From File. Import raw-read files 
(Sample_xx_R1.fastq.gz and Sample_xx_R2.fastq.gz) into Geneious 
3. Download the Reference Genome from the NCBI database. For 
example, M. tuberculosis NC_000962.3. 
a. In the Left panel | Go to NCBI | Nucleotide. 
b. Enter NC_000962.3 | Click Search. 
c. Once the genome has been found, click Download Full Sequence(s).  
d. Download the NC_000962.3 reference genome (The icon changes 
to a green circular genome when completed). 
e. Drag and drop the NC_000962.3 reference genome into the working 
folder. 
4. Mapping the isolate sequence to the reference genome 
a. Hold CTRL and select the both R1 and R2 raw read files (imported), 
and the reference genome (NC_000962.3) (downloaded).  
b. Click Align| Assemble| Map to Reference. 
c. Check the settings*  
i. Reference Sequence = NC_000962.3  
ii. Mapper = Bowtie2 – fast and accurate read mapper 
 ii 
 
iii. Trim Before Mapping = Do not trim 
iv. Results: Select all options 
v. Results | Save consensus sequences | Options  
vi. Threshold = Highest Quality 
vii. Threshold for sequences without quality = 95% 
viii. If no coverage call = ‘–’ 
d. When mapping to reference is complete, a new folder will be created 
containing four files: 
i. Assembly Report 
ii. Consensus 
iii. Contig 
iv. Unused Reads 
e. A contig is contiguous linear stretch of DNA or RNA consensus 
sequence constructed from a number of smaller, partially overlapping, 
sequence fragments (reads). To view Contigs, click Contig file | Slide the 
zoom bar to view the sequence reads. The statistics about the mapping can 
be viewed by clicking % tab in view statistics. 
*This setting may vary depending on the objective of analyses and quality 
of Fastq reads.  
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Response to the Examiner’s Comments 
Examiner-1 comments and responses 
Strengths: There are several interesting and significant findings described 
in this thesis. 
Identification of a set of genes absent in H37Rv but present in the Rangipo 
strains (in particular the five genes shown in Figure 3.1) is a major finding 
that can help explain differences between the Rangipo strains and H37Rv. 
The genes that are present only in the Rangipo stains appear to be 
associated with vital cellular functions. This may mean that cellular 
physiology of Rangipo strains is not identical to that of H37Rv. In such a 
case, the transmissibility or virulence of Rangipo strains could be influenced 
by these genes. For these reasons, the reported findings are significant. 
Molecular epidemiological studies described in Chapter 4 of M. tuberculosis 
strains isolated in Tasmanai in 2014-2017 are straightforward, thorough and 
conclusions made should be useful in making relevant public health policy 
decisions. Equally interesting is the TASMDR1 case. Seeking out VTB1 to 
undertake a detailed analysis of TASMDR1 was a very good strategy. 
The current draft of this thesis should be revised to address the minor 
comments, queries and recommendations that I have made. Most of these 
comments are minor, but some require clarification of the statements made 
or methods used. 
 
Response: I thank the examiner for acknowledging the significance of the 
work undertaken. The grammatical errors noted by the examiner have been 
corrected in the revised version of the thesis. The thesis has been 
thoroughly proof read before final submission to the chair of examiners. 
Here, I include responses to the comments, queries and recommendations 
made by examiner 1. 
To be precise, this is ‘resequencing’ as the reference genome was used to 
generate ‘a complete’ genome sequence for each strain. 
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Response: Thank you for the comment. In this work, new, previously-
unsequenced isolates of M. tuberculosis were sequenced. In order to 
scaffold the FASTQ sequence reads, an established reference genome of 
M. tuberculosis was used i.e. H37Rv. Therefore, re-sequencing of 
previously-sequenced isolates of M. tuberculosis was not performed in this 
work. To fully clarify this point, the following statement has been added to 
the revised thesis: Whole-genome sequencing of nine isolates representing 
the Rangipo genotype was performed on an Illumina MiSeq platform. The 
sequence data of each isolate was mapped to the reference M. tuberculosis 
strain H37Rv to generate a consensus genome. Page ii. 
1. This statement is not necessary. 
Response: The statement, ‘WGS offers the capability to decipher the 
biology and perform molecular epidemiological typing of M. tuberculosis’ 
has been removed as suggested by the examiner. Page v. 
2. To be factually correct, I recommend adding ‘sputum smear microscopy 
based on AFB staining’ as this modality is still extensively used in resource 
limited setting (where most of the TB patients are first diagnosed and 
treated).  
Response: The recommended information has been added to the revised 
thesis with the following statement: The first group experience symptoms of 
TB (for example fever, weight loss and haemoptysis), transmit infection and 
are usually detected by sputum smear microscopy and culture-based 
diagnostic tests. Secondly, patients with latent TB, although infected, do not 
exhibit symptoms or transmit the infection and are undetectable in culture-
based tests (Barry et al., 2009; Desikan, 2013; Esmail et.al, 2014). Page 2. 
3. No WGS is not suited for predicting functional roles of genes. WGS is good 
at providing raw DNA sequence at high resolution and accuracy. 
‘Functional roles’ cannot be predicted with sufficient accuracy as WGS is 
not meant for this purpose.  
Response: The following statement’ Whole-genome sequencing poses an 
advantage to ideally identify all the clinically relevant mutations and predict 
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wide range of drug resistance determining mutations (Wells et al., 2013) as 
compared to Xpert MTB/RIF and line probe assays which are limited to 
detect mutations in specific gene locus (Sanchez-Padilla et al., 2015).’ has 
been added in the revised thesis after accepting the examiners comment. 
Page 16. 
4. What aspects of the data were analysed? How were they validated? Briefly 
describe. 
Response: The whole genome sequence data obtained as Fastq files were 
analysed for variant detection, infer phylogenetic relationship, establish 
transmission networks, and identify differential genome content. Data 
analyses for specific experiments have been described in the methods 
section of each chapter. A new table (table 3) has been added in the revised 
thesis where tools and databases used for analyses of genomic data in this 
study have been summarised. We did not validate any bioinformatics 
pipeline during the study which is one of the limitations of the study and is 
subject to future study. Page 55. 
5. Very important finding. Also, please verify if there is any sequence 
homology of Rv3109 and Rv0869c to the genes that you have identified in 
the Rangipo strain (MoaA and MoaB in the Rangipo strain as shown in 
Figure 3.1). 
Response: Thank you for recognizing our work. A preliminary investigation 
of genome sequence data of Rangipo strain suggests the presence of 
sequence homology of Rv3109 and Rv0869c with 100% similarity at the 
nucleotide level in the Rangipo strain. Page 73. 
6. A more stringent assessment would have been Southern blot analysis. You 
should mention that Southern blotting was not performed. 
Response: To clarify the method used in confirming the presence of 
differential genes in Rangipo strains following sentence has been added in 
the updated thesis: PCR rather than Southern Blotting was performed on 
the Rangipo isolates and H37Rv using primers for the genes (MT3426, 
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MT3427, MT3428, MT2082 and MT1360) to confirm their presence and 
absence as indicated by the genome sequence analysis. Page 72. 
7. Which mutations were considered? 
Response: Drug resistance determining mutations were predicted using 
PhyResSe database (Feuerriegel et al., 2015) which identifies the mutations 
related to first- and second-line drug resistance in tuberculosis. A new 
statement has been added to the main text including examples of some of 
the mutations detected by PhyResSe. Page 74. 
8. You might also want to state (if you have the data) whether there are genes 
in H37Rv that are not present in the Rangipo strains. 
Response: Thank you for the comment. A preliminary analysis based on 
whole genome sequence data showed the absence of four genes (with 
functional annotation and excluding PE, PPE, PGRS, transposes and 
prophages) in the Rangipo strain that were present in the reference H37Rv. 
These include, Rv1758 (cutinase 1), Rv1760 (diacylglycerol 
acetyltransferase), Rv2653c (toxin), Rv2654c (antitoxin). This has been 
added to the conclusion and recommendation section 3.4 of the updated 
thesis. Page 81. 
9. While using H37Rv genome as template for assessment of known 
mutations that confer resistance to the TB treatment drugs (relevant in the 
context of this specific clinical isolate) is fine, it appears a bit strange that 
you chose not to use other more clinically relevant strains (such as 
CDC1551, Erdman etc) especially since you recommend using multiple 
stains for alignment studies (in the previous chapter). 
Response: This particular analysis (section 5.3.2) was done to deposit the 
genome sequence data of TASMDR1 in the public databases. Here, we did 
not aim to compare the genome of TASMDR1 with different reference 
strains and therefore it was mapped against H37Rv to identify SNPs and 
drug resistant determining mutations. Page 105. 
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Examiner-2 comments and responses 
Thank you for asking me to be an external examiner for this thesis by Sanjay 
Gautam for consideration for the degree of Doctor of Philosophy. Overall I 
feel that it meets the requirements to be awarded a PhD but there are some 
concerns and minor points that I detail below that I do feel need to be 
addressed. 
Response: I would like to thank the examiner for acknowledging and 
reviewing the work undertaken. The grammatical errors noted by the 
examiner have been corrected in the revised version of the thesis. The 
thesis has been thoroughly proof read before final submission to the chair 
of examiners. Here, I include responses to the comments, queries and 
recommendations made by examiner 2. 
1. There is also a constant flux between British and US English throughout the 
thesis. I recommend choosing while style and then being consistent. 
Response: The discrepancies between British and US English have been 
corrected by adopting the British English format.  
2. Finally, there are issues in the latter part of the thesis with distinctions 
between protein and gene names. Genes start with a lower‐case letter and 
are italicised, proteins start with a capital letter and are not italicised. There 
are many references to italicised capitalised names and it is not clear if one 
is referring to the protein or the gene. 
Response: The gene names have now been corrected to lower case and 
italicised while the name of the protein has not been italicised and start with 
the capital letter.  
3. Much of the content of the thesis appears to be published. It was not clear 
why the published papers were simply not included as chapters as 
presumably these would have been freer of errors and already peer‐
reviewed. Please ignore this comment if the University of Tasmania does 
not allow for mixed or theses by publication. 
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Response: The thesis format used is one of the accepted formats for PhD 
theses at the University of Tasmania whereby published and under review 
papers are appended but a full thesis with conventional chapters is also 
written i.e. Page 5 of the Higher Degree by Research Thesis Preparation, 
Submission and Examination Policy, University of Tasmania “2. a written 
text containing a combination of peer reviewed publications, articles 
undergoing peer-review or revision, and conventional chapters presented 
as typescript”.   
4. I note that some of the content is in press or has been submitted. Could 
updates be provided as to whether this has now been published. 
Response: The paper entitled “Potential cross-border translocation of multi-
drug resistant tuberculosis in latent form to Australia” and A Step by-Step 
Beginner’s Protocol for Whole-genome Sequencing of Human Bacterial 
Pathogens” is now published while next paper “. 
5. Chapter 2 is a methods paper – I will provide some more details below but 
the changes to well‐known and used protocols that are suggested do not 
appear to be validated. There is no comparison made between the 
manufacturers’ protocols and the submitted protocol and therefore there is 
an outstanding question around the validity of the changes made. 
Response: The submitted protocol was based primarily on the 
manufacturer’s protocol except for the consumables used and specific 
reaction steps. We modified a number of the DNA extraction steps to obtain 
a sufficient quantity of contamination free template. Similarly, we replaced 
library normalization plates and Nextera XT tagment amplicon (NTA) plates 
with conventional polymerase chain reaction (PCR) PCR tubes which may 
represent a cost-effective alternative. In addition, we have recommended 
the use of equal DNA concentrations of each library during library 
normalization to ensure better coverage and minimize bias. The protocol 
was adopted based on its reproducibility and reliability and has been cited 
across many of our publications (Mac Aogain et al, 2016, Gautam et al., 
2017, Gautam et al., 2018, Leong et al., 2018).  
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6. The bioinformatics analyses presented throughout the thesis are confusing. 
They often switch between multiple pieces of software used for very 
different purposes i.e. mapping tools, then de novo assembly, then calling 
SNPs, etc. The purpose of a methods section is to be detailed enough to 
allow one to reproduce the analyses. While the wet lab sections do this well, 
I do not believe anyone could reproduce the findings of the bioinformatics 
analysis as simple things like parameters are not given. 
Response: The switches between the data analyses tools and databases 
was due to the objective of the study. For example, SNPs were called either 
to identify drug resistance determining polymorphisms or to establish 
transmission network. The data analyses pipeline differed in each of these 
cases. The bioinformatic analyses steps outlined in chapter 2 includes basic 
steps in genome assembly and SNP detection. The objective specific use 
of different pipelines has been discussed within the methods section of each 
chapter. To make the data analyses pipeline clearer, a new table (Table 3) 
has been added in chapter 2 of the revised thesis where database and tools 
utilized have been discussed.  
7. There are multiple references in the thesis to tuberculosis being caused by 
a single infectious agent, but then the acknowledgement elsewhere that it 
is caused by a complex of species. Please be consistent – the disease of 
tuberculosis is caused by a number of species that make up the 
Mycobacterium tuberculosis complex. 
Response: Thank you for specifying inconsistencies. Relevant changes 
have been made. For example, a revised statement ‘Tuberculosis (TB) is a 
major cause of global mortalities causing 1.6 million deaths in 2017 alone 
due to different species of Mycobacterium tuberculosis complex’ has been 
included in the abstract. Page ii. 
8. “the colon tissue biopsy specimen detected the presence” – a specimen 
cannot detect things in itself. Therefore specific what testing was performed 
on the specimen to identify the bacteria. 
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Response: Mycobacterium tuberculosis were detected in the colon tissue 
biopsy sample using MGIT culture system. The suggested edits have been 
accepted in the revised draft of the thesis. Page iv. 
9. Brosch et al. 2002 is a very old reference when talking about TB ancestry 
and there is much more newer data available. I would recommend 
https://www.nature.com/articles/nrmicro.2018.8 instead. M. africanum is 
less likely to be referred to as a separate species now – make sure to read 
Gagneux’s latest papers on this. Page 1. 
Response: I thank the reviewer for the suggestion. The recommended 
reference, Gagneux, 2018 has been added in the revised thesis.  
10.  “BCG vaccine was covered in more than 86%” – use of language. Does 
this mean it is on the essential medicines list or national immunisation 
programmes of over 86% of countries? 
Response: The statement was made to represent following data, “In 2016, 
the global BCG vaccine coverage estimate was 90% reported from 169 
countries, and all WHO regions have an average BCG vaccine coverage 
greater than 86%”. The following statement has been included in the revised 
thesis: The preventive Bacillus Calmette –Guérin (BCG) vaccines average 
coverage was more than 86% across all WHO regions (World Health 
Organization, 2017b). Page 5. 
11. Note that there are errors in Zhang et al. 2013 analysis of BCG. The more 
updated ref is https://www.nature.com/articles/srep15443 
Response: The Zhang et al. 2013 paper has been replaced with the 
Abdallah et al. 2015 paper. Page 7. 
12. BCG is given routinely in London, and this doesn’t meet the high‐risk 
definitions given in the text 
Response: We agree with the examiner's comment. “Europe” has been 
updated with Western European countries as mentioned in the original text. 
Page 8. 
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13. Some of the discuss around membership of the M. tuberculosis complex is 
a little outdated. Current thinking is that they are variants of the same 
species: 
https://ijs.microbiologyresearch.org/content/journal/ijsem/10.1099/ijsem.0.
002507#tab2 
Response: Thank you for the reference. A new statement from the 
recommended reference (Riojas et al. 2017) has been incorporated in the 
text. Page 19. 
14. it is wrong to say that TB treatment is the longest regimen to treat an 
infectious agent. There are bacterial diseases that need longer courses of 
treatment, e.g. chronic Lyme and Q fever, and viral diseases that need 
lifelong therapy, e.g. HIV 
Response: This statement has been modified to: “Treatment of TB, 
therefore, involves one of the longest regimes directed against an infectious 
disease” Page 26. 
15. The findings from Gardy et al. are misquoted here – recommend looking 
more closely at the findings described in the paper and the impact of MIRU 
versus SNP‐based typing. 
Response: Thank you for the comment. The sentence has been updated 
with: Whole-genome sequencing identified identical MIRU-VNTR 
genotypes which along with the analyses of patient’s social networks 
detected the presence of a common progenitor during a TB outbreak that 
existed before the onset of transmission (Gardy et al., 2011). This outbreak 
was further related to a social event of the use of crack cocaine (Gardy et 
al., 2011). Page 38. 
16. As noted above, it is all well and good to describe a new wet lab protocol 
but there are no results demonstrating that the results from it are as good 
as published protocols. 
Response: The aim of introducing modifications in the manufacturer’s 
protocol was to generate a step-by-step protocol that can be used by 
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laboratory personnel with no prior experience with next-generation 
sequencing. There was no comparison made with any published protocols 
rather we aimed to reproduce the method to obtain high quality genomic 
data for downstream analyses. This method of generating whole-genome 
sequence data of bacteria including M. tuberculosis was based on the 
manufacturer’s instructions (Illumina, Inc. 2012). Modifications were done in 
terms of the usage of consumables and library normalization step to 
maximize the quality of output data (Gautam et al., 2019a). The proposed 
method was not compared for its sensitivity and accuracy with any 
published protocol; however, we were able to reproduce the protocol for 
studies involving M. tuberculosis and other bacterial pathogens (Gautam et 
al., 2019; Gautam et al., 2018; Gautam, Mac Aogáin, & O’Toole, 2017; 
Leong et al., 2018; Mac Aogáin et al., 2016). Page 56. 
17.  Also as noted above, there is lots of confusion when it comes to describing 
the bioinformatics pathways. For example, FastQC is mentioned twice, as 
a standalone piece of software and as part of Galaxy. Geneious is used to 
map and find variants but then BWA and SAMtools are mentioned. No 
details are provided around parameters for any software used. The 
contribution by the collaborator at Trinity College Dublin is also not clear. 
How has the final pipeline been validated, particularly against published 
pipelines? 
Response:  The repeated information regarding FastQC has been deleted 
in the revised thesis. Geneious was initially used for the mapping and 
variant calling. Later, BWA and SAMtools were used by a collaborator at 
Trinity college Dublin to perform similar analyses. In this way, we used 
different platforms to reach a final conclusion. No validation experiments 
were performed for a new pipeline, rather we based our analyses on the 
published works of literature to design cut-offs and establish a working 
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pipeline. This was one of the limitations of the bioinformatic approach, but 
this does not significantly detract the epidemiological analyses done in the 
current study. Page 55. 
18. I would strongly recommend against using random multiple base matching 
– why would you only map uniquely and exclude reads that could match 
multiple places. Otherwise, SNP information is extremely difficult to 
interpret. Also throughout this and subsequent chapters here is mention of 
SLVs and SNPs, but no description of indels that can be detected and the 
sizes obtained. In addition there is constant confusion in the methods 
sections about mapping versus de novo assembly, why you would use one 
over the other, etc. 
Response: We employed random multiple base matching as mapping and 
SNP detection using BWA and SAMtools allowed us to detect SNPs and 
genes that were completely missing in the Rangipo strain consistently. The 
presence/absence of genes were confirmed by PCR amplification and 
Sanger sequencing. The five genes that were detected in the Rangipo strain 
but absent in H37Rv were regions of insertions in ORFs in Rangipo strain 
relative to H37Rv. Similar insertion events were reported by Fleischmann et 
al.,2002 in strain CDC1551. In this study, we were more focused on 
detecting differential gene content in the Rangipo strain and therefore we 
did not report all the indels. Furthermore, we performed de novo assembly 
only when we were looking to deposit the genome in the public database. 
All other analyses were done after mapping the raw sequence with different 
reference genomes. Page 63. 
19.  Lots of details missing about the phylogenetic methods used, particularly 
choice of GTR substitution model, methods for generating trees, 
bootstrapping, etc. There is also a lack of information about how displayed 
trees in this thesis were rooted. 
Response: For phylogenetic tree building, PhyML was used where 10 
starting trees were selected and bootstrapping was performed over 100 
replicates. Furthermore, the tree was rooted to Mycobacterium canetti. This 
information has been added in the revised thesis. Page 73. 
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20. The section on consensus genome assembly is slightly out of place. Why 
was this done on only one isolate? Why not assemble all of them? How was 
the assembly improved beyond a simple contig assembly? 
Response: Prior to this work, there were no publicly available genome 
sequences of Rangipo strains of M. tuberculosis in the DDBJ/ENA/GenBank 
databases. The purpose of section 3.2.4.5 was to generate and publish an 
assembled consensus genome of M. tuberculosis Rangipo. Strain 494 was 
selected as a representative genome of the Rangipo strains to enter into 
DDBJ/ENA/GenBank. The genomes of the other eight Rangipo isolates 
differed by ≤15 SNPs from strain 494. Page 74. 
21.  It is not clear what conclusions around virulence you are actually trying to 
reach. The mutations in virulence genes would appear to support reduced 
virulence for Rangipo strains, but you overall conclude the opposite. Is this 
simply due to inclusion of similar genes as CDC1551? 
Response: Here we reported polymorphisms in genes that have previously 
been related to the virulence of M. tuberculosis in the published literature. 
For example, disruption of aceAa has been associated with the reduced 
survival of M. tuberculosis in the lungs and spleen of infected mice (Munoz-
Elias and McKinney JD, 2005). To determine the effect of the 
polymorphisms identified in the Rangipo strain on the virulence of M. 
tuberculosis, downstream functional studies involving site-directed mutants 
would need to be conducted. Page 76. 
22. There are two major weaknesses in this chapter. The first is the selection of 
strains – why were a single year’s group of strains not sequenced. There 
were not many so it wouldn’t be too expensive.  
Response: As Tasmania is a low TB incidence state (approx. 1.6/100,000), 
the number of TB cases from a single year is very low. Furthermore, not all 
M. tuberculosis specimens were culturable. In addition, there is no single 
reference laboratory for TB in Tasmania which meant that isolates had to 
be sourced from multiple intra- and inter-state laboratories. To reach the 
 xiii 
 
number of isolates examined in this thesis work, it was necessary to 
examine isolates from a greater number of calendar years.  
23.  Second, there is an important finding of BCGosis that is completely ignored 
in the results and discussion. The only real demonstration is in TABLE 6. It 
has been described as tuberculosis, which is incorrect, but is this simply a 
result of bladder cancer treatment with BCG? 
Response: The BCG was isolated from urine specimen taken from a patient 
undergoing bladder cancer treatment with BCG. It was included in the study 
to provide a genetic comparison with the M. bovis TB case in order to 
establish that the latter TB case was indeed caused by M. bovis and not 
BCG.  A new paragraph has been added in the revised thesis regarding the 
preliminary analysis of the BCG strain. Page 94. 
24.  How were the 18 strains chosen? Why not sequence all? What is the risk 
of bias introduced here? 
Response: There were 29 TB cases notified in Tasmania during the 
calendar years, 2014-2016. All of the bacteriologically confirmed cases with 
isolates available (n=18) were included in this study for whole genome 
sequencing. Page 84. 
25. You describe a strange mix of pipelines in chapter 3 so which was actually 
used for this chapter? 
Response: To make it clearer, section 4.2.4 has now been updated and 
chapter 4 specific data analyses pipeline included. Page 85. 
26.  “Osteomyelitis” isn’t a specimen. Was it pus or bone? Similarly “tissue” is 
not enough description. 
Response: The information presented was based on the available public 
health surveillance records. The available record of the patient did not 
explain if it’s a pus or bone specimen. The tissue sample was obtained from 
a colon biopsy and this has been revised in table 7. Page 88. 
27. M. bovis BCG detection in urine is not tuberculosis.  
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Response: I agree with the examiner’s comment. The BCG was isolated 
from a urine specimen taken from a patient undergoing bladder cancer 
treatment with BCG. It was included in the study to provide a genetic 
comparison with the M. bovis TB case in order to establish that the latter TB 
case was indeed caused by M. bovis and not BCG. Page 88. 
28.  Similar problem with phylogenetics. Methods? Bootstraps? Root? 
Response: For phylogenetic tree building, PhyML was used where 10 
starting trees were selected and bootstrapping was performed over 100 
replicates. Furthermore, the tree was rooted to Mycobacterium canetti. This 
information has been added in the revised thesis. Page 90. 
29.  “These cases of drug susceptible pulmonary TB were detected in the 
gastric aspirate” how is it pulmonary if in a gastric sample? 
Response: The gastric aspirate samples were obtained for pulmonary TB 
detection in infants. We confirmed these as cases of pulmonary TB in 
consultation with the treating physician. Page 88. 
30.  I would expect an interesting finding such as M. bovis would be described 
more fully. Age of patient? Symptoms? Presentation, etc? 
Response: The clinical data that was available for this case was limited. The 
patient variables available consisted of age, specimen type, and comorbidity 
(section 4.3.4) and has been reproduced in section 4.4 of the updated 
thesis. Page 97. 
31.  The methods section only focuses on sequencing a single isolate, yet the 
results talk about a second isolate being sequenced. 
Response: The same method was applied for sequencing both the isolates. 
The first isolate TASMDR1 was sequenced during our work described in 
chapter 4. The second sample, VTB1, was obtained later following travel to 
Viet Nam to collect the isolate from Ho Chi Minh City and then sequenced.  
32.  Aforementioned confusion between mapping and de novo assembly. 
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Response: Thank you for the comment. Mapping with the reference strain 
H37Rv was done primarily to identify the number and types of single 
nucleotide polymorphism and detect the presence of drug resistance 
determining mutation. de novo assembly was done to assemble the contigs 
so that they can be ordered with respect to the reference genome for their 
deposition in the public database (Gautam et al.,2018). Page 102.  
33. I am really unclear what the final sentence is saying here 
Response: The final sentence in page 103, “The number of variants in the 
MDR-TB strain with respect to the H37Rv reference genome were 
determined using the SAM-tools analyses suite” is describing the process 
of determining the number of variants present in the MDR-TB strain as 
compared to M. tuberculosis reference strain, H37Rv. Furthermore, we 
incorporated the patient information along with the SNP analyses data to 
infer a transmission network. Page 103. 
34.  Are the resistance determining mutations similar or identical to TASMDR1? 
Response: The resistance determining mutations present in TASMDR1 and 
VTB1 were exactly the same. The sentence has been rewritten as, ‘The 
drug resistance profile and lineage typing of VTB1 was identical to 
TASMDR1, i.e. VTB1 belonged to East Asian L2 (Beijing) and conferred 
exactly the same drug resistance determining mutations as of TASMDR1 
i.e. isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin.’ Page 
108. 
35.  No evidence is presented about improving the methodology. What was the 
baseline protocol used in Dublin, how was it improved and how was the 
improvement validated? 
Response: Thank you for the comment. The protocol was originally 
designed at Trinity College, Dublin and was later adopted at the University 
of Tasmania. The new thing that we did in this protocol was the replacement 
of consumables and certain steps recommended by the manufacturer. The 
major advantage was decrease in the cost related to consumables. 
Furthermore, this protocol worked well for Gram positive, Gram negative 
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and acid-fast bacilli. Some of the changes in protocol across the 
experiments include the process of obtaining bacterial DNA from the liquid 
culture which is dependent upon cell wall composition of the bacteria. Based 
on this protocol, we have performed experiments on Gram positive, Gram 
negative and acid-fast bacilli and have been able to reproduce each time 
with the generation of high -quality data (minimum read depth of 20). 
Contrarily, we did not validate any bioinformatics pipeline during the study 
which is one of the limitations of the study and is subject to future study. 
Page 115. 
36.  Linnaean names are not properly italicised in titles of papers 
Response: Thank you for the comment. The suggested edits have been 
made.  
37. Reference half missing 
Response: This incorrect reference has now been deleted. Page 167 
 
Response to in-text comments by examiner 2 not listed in the comment file.  
38. If state this then it is worth then stating what the proportions are in HIV‐
infected and uninfected patients. 
Response: The data on the proportion of HIV-infected and uninfected 
patients have been updated in the revised thesis and include the following 
statement, 87% (n=1255) of TB cases in Australia were detected among 
those with known HIV status where 27 cases were associated with HIV 
positive individuals. Sixty two percent had pulmonary TB of which 87% were 
bacteriologically confirmed (World Health Organization, 2018). There were 
25 pulmonary TB cases identified as MDR/RR-TB during 2017 (World 
Health Organization, 2018). Page 6. 
39.  Mono or MDR? 
Response: These were categorised as MDR/RR-TB. The statement has 
been updated. Page 6. 
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40.  Has chapter 3 been published? 
Response:  Yes, Chapter 3 is published in the Journal of Infectious 
Diseases and can be accessed here: 
https://doi.org/10.1080/23744235.2017.1330553. Page 62. 
41.  What about Indels? Particularly for PZA resistance? 
Response: Yes, indels were determined for PZA resistance using 
PhyResSe database and sequence analyses done after BWA/SAMtools 
mapping and variant finding. Page 65. 
42.  Was this tested and found to be the best model (e.g. using Akaike or 
Bayesian information criteria?) 
Response: Unfortunately, we did not aim to test different models of 
phylogenetic tree building. Page 64. 
43.  Filtering criteria for SAM-tools? 
Response: The SAMtools Mpileup was run with the following command: 
SAMtools Mpileup -DSugBf $ref -Q30 -q30 -o40 -e20 -h100 -m2 
A SNPSIFT quality filter of 'QUAL >= 999' was imposed on detected variants 
with minimum 5-fold coverage across all strains analyzed. Page 65. 
44.  But also, as you note, a number of lineage 4 strains. 
Response:  Yes, these genes (some but not all) were also found in other 
Lineage 4 strains of M. tuberculosis. In this section we were more focused 
on the outbreak strain. Page 76. 
45.  Details of the BCG case? Type of BCG? Was it mapped to the genomics 
data available on BCG? 
Response: This case of M. bovis BCG was related to a patient obtaining 
BCG for his bladder cancer treatment and was therefore not investigated 
further. However, an analysis of the genome was performed using CGE 
database (http://www.genomicepidemiology.org/). A paragraph regarding 
Tasmanian BCG strain has been added in the revised version of the thesis. 
Page 94. 
46.  Size range of insertions/deletions in TASMDR1 
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Response: The indels in TASMDR1 isolate ranged in their size of 1 to 501 
base pairs. Page 105. 
 
47.  This wasn’t clear ‐ what were the new steps? What are the benefits? 
Response: Thank you for the comment. The protocol was originally 
designed at Trinity College, Dublin and was later adopted in University of 
Tasmania. The new thing that we did in this protocol was the replacement 
of consumables and certain steps recommended by the manufacturer. The 
major advantage was decrease in the cost related to consumables. 
Furthermore, this protocol worked well for Gram positive, Gram negative 
and acid-fast bacilli. Some of the changes in protocol across the 
experiments include the process of obtaining bacterial DNA from the liquid 
culture which is dependent upon cell wall composition of the bacteria. Based 
on this protocol we have performed experiments on Gram positive, Gram 
negative and acid-fast bacilli and have been able to reproduce each time 
with the generation of high -quality data (minimum read depth of 20). 
Contrarily, we did not validate any bioinformatics pipeline during the study 
which is one of the limitations of the study and is subject to future study. 
Page 115. 
 
